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Preamble
Guidelines and Expert Consensus Documents aim to
present all the relevant evidence on a particular issue
in order to help physicians to weigh the beneﬁts and
risks of a particular diagnostic or therapeutic proce-
dure. They should be helpful in everyday clinical deci-
sion-making.
A great number of Guidelines and Expert Consensus
Documents have been issued in recent years by the
European Society of Cardiology (ESC) and by different
organisations and other related societies. This profu-
sion can put at stake the authority and validity of
guidelines, which can only be guaranteed if they have
been developed by an unquestionable decision-making
process. This is one of the reasons why the ESC and
others have issued recommendations for formulating
and issuing Guidelines and Expert Consensus
Documents.
In spite of the fact that standards for issuing good
quality Guidelines and Expert Consensus Documents are
well deﬁned, recent surveys of Guidelines and Expert
Consensus Documents published in peer-reviewed jour-
nals between 1985 and 1998 have shown that methodo-
logical standards were not complied with in the vast
majority of cases. It is therefore of great importance
that guidelines and recommendations are presented in
formats that are easily interpreted. Subsequently, their
implementation programmes must also be well con-
ducted. Attempts have been made to determine whether
guidelines improve the quality of clinical practice and
the utilisation of health resources.
The ESC Committee for Practice Guidelines (CPG)
supervises and coordinates the preparation of new
Guidelines and Expert Consensus Documents produced
by Task Forces, expert groups or consensus panels. The
chosen experts in these writing panels are asked to pro-
vide disclosure statements of all relationships they may
have which might be perceived as real or potential con-
ﬂicts of interest. These disclosure forms are kept on ﬁle
at the European Heart House, headquarters of the ESC.
The Committee is also responsible for the endorsement
of these Guidelines and Expert Consensus Documents or
statements.
2244 ESC GuidelinesThe Task Force has classiﬁed and ranked the useful-
ness or efﬁcacy of the recommended procedure and/or
treatments and the Level of Evidence as indicated in
the tables below:
Classes of Recommendations
Class I Evidence and/or general agreement that a
given diagnostic procedure/treatment is
beneﬁcial, useful and effective;
Class II Conﬂicting evidence and/or a divergence
of opinion about the usefulness/efﬁcacy of
the treatment;
Class IIa Weight of evidence/opinion is in favour of
usefulness/efﬁcacy;
Class IIb Usefulness/efﬁcacy is less well established
by evidence/opinion;
Class III
a Evidence or general agreement that the
treatment is not useful/effective and in
some cases may be harmful.
a Use of Class III is discouraged by the ESC.
Levels of Evidence
Level of Evidence A Data derived from multiple
randomised clinical trials or
meta-analyses
Level of Evidence B Data derived from a single
randomised clinical trial or
large non-randomised studies
Level of Evidence C Consensus of opinion of the experts
and/or small studies, retrospective
studies, registries
Introduction
Pulmonary arterial hypertension (PAH) is deﬁned as a
group of diseases characterised by a progressive increase
of pulmonary vascular resistance (PVR) leading to right
ventricular failure and premature death.
1 The median life
expectancy from the time of diagnosis in patients with
idiopathic PAH (IPAH), formerly known as primary pul-
monary hypertension (PPH), before the availability of dis-
ease-speciﬁc (targeted) therapy, was 2.8 years through
the mid-1980s.
2 PAH includes IPAH
3 and pulmonary
hypertension associated with various conditions such as
connective tissue diseases (CTD), congenital systemic-
to-pulmonary shunts, portal hypertension and Human
Immunodeﬁciency Virus (HIV) infection.
4 All these condi-
tions share equivalent obstructive pathological changes
of the pulmonary microcirculation
5,6 suggesting shared
pathobiological processes among the disease spectrum
of PAH.
7
In the past decade, we have witnessed major ad-
vances in our understanding of the mechanism of disease
development, in the diagnostic process, and in the treat-
ment of PAH.
The identiﬁcation of mutations in the bone morpho-
genetic protein receptor 2 (BMPR2) in the majority of
cases of familial PAH (FPAH) has been a major ad-
vance in the elucidation of the pathogenic sequence
in PAH.
8,9 A variety of cellular abnormalities have
been described in the pulmonary vasculature of af-
fected patients that may play important roles in the
development and progression of PAH.
7 These include
pulmonary endothelial dysfunction
10 characterised by
altered synthesis of nitric oxide, thromboxane A2,
prostacyclin and endothelin, impaired potassium chan-
nels and altered expression of the serotonin trans-
porter in the smooth muscle cells and enhanced
matrix production in the adventitia.
7
The diagnosis is now more clearly deﬁned according to
a new clinical classiﬁcation and with consensus reached
on algorithms of various investigative tests and proce-
dures that exclude other causes and ensure an accurate
diagnosis of PAH.
11 In addition, non-invasive markers of
disease severity, either biomarkers or physiological tests
that can be widely applied, have been proposed to reli-
ably monitor the clinical course.
11,12
Finally, the numerous controlled clinical trials
performed recently in PAH can allow us to abandon a clin-
ical-based treatment strategy and adopt an evidence-
based therapy that includes new classes of drugs such
as prostanoids,
13 endothelin receptor antagonists
14 and
type 5 phosphodiesterase inhibitors.
15
The present guidelines are intended to provide clear
and concise indications for the practical use of the new
clinical classiﬁcation, and a brief description of the
new pathological classiﬁcation and of the recent patho-
genetic insights. The diagnostic process will be discussed
in order to propose a logical sequence of investigations
for aetiology identiﬁcation, disease assessment and fol-
low-up. Special emphasis will be devoted to the evi-
dence-based treatment algorithm that has been deﬁned
according to the ESC proposals for the Level of Evidence
classiﬁcation and the Grade of Recommendation
16 for
the available therapies.
Clinical classiﬁcation of pulmonary
hypertension
Pulmonary hypertension (PH) is deﬁned by a mean pul-
monary artery pressure (PAP) >25 mmHg at rest or >30
mmHg with exercise.
17 Current classiﬁcation of PH is pre-
sented in Table 1. It is a result of extensive discussion
and represents a consensus accommodating our present
understanding of pathophysiology as well as of clinical-
based differences or similarities within PH. Understand-
ing and correct clinical application of the classiﬁcation
should be aided by the following discourse.
PH was previously classiﬁed into 2 categories: PPH or
secondary PH depending on the absence or the presence
of identiﬁable causes or risk factors.
3,17 The diagnosis of
PPH was one of exclusion after ruling out all causes of PH.
In 1998, during the Second World Meeting on PH held
in Evian – France, a clinical-based classiﬁcation of PH
was proposed.
18 The aim of the ‘‘Evian classiﬁcation’’
was to individualise different categories sharing similar-
ities in pathophysiological mechanisms, clinical presen-
tation and therapeutic options. Such a clinical
ESC Guidelines 2245classiﬁcation is essential in communicating about individ-
ual patients, in standardising diagnosis and treatment, in
conducting trials with homogeneous groups of patients,
and lastly in analysing novel pathobiological abnormali-
ties in well characterised patient populations. Obviously,
a clinical classiﬁcation does not preclude other classiﬁ-
cations such as a pathological classiﬁcation based on his-
tological ﬁndings, or a functional classiﬁcation based on
the severity of symptoms. The 2003 Third World Sympo-
sium on PAH held in Venice–Italy provided the opportu-
nity to assess the impact and the usefulness of the
Evian classiﬁcation and to propose some modiﬁcations.
It was decided to maintain the general architecture
and philosophy of the Evian classiﬁcation. However,
some modiﬁcations have been proposed, mainly: to
abandon the term ‘‘primary pulmonary hypertension –
PPH’’ and to replace it with ‘‘idiopathic pulmonary arte-
rial hypertension – IPAH’’, to reclassify pulmonary
veno-occlusive disease (PVOD) and pulmonary capillary
haemangiomatosis (PCH), to update risk factors and
associated conditions for PAH, and to propose some
guidelines in order to improve the classiﬁcation of con-
genital systemic-to-pulmonary shunts (Table 1). The
aim of these modiﬁcations was to make the ‘‘Venice clin-
ical classiﬁcation’’ more comprehensive, easier to follow
and widespread as a tool.
Idiopathic pulmonary arterial hypertension
The term PPH was retained in the Evian classiﬁcation
because of its common use and familiarity, and because
it was emblematic of 50 years of intense scientiﬁc and
clinical research. However, the use of the term ‘‘pri-
mary’’ facilitated the reintroduction of the term ‘‘sec-
ondary’’ that was abandoned in the Evian version
because it was used to describe very heterogeneous
conditions. In order to avoid any possible confusion in
Venice it was decided that the ﬁrst category termed
‘‘pulmonary arterial hypertension – PAH’’ should in-
clude three main subgroups: [1.1] idiopathic pulmonary
arterial hypertension – IPAH, [1.2] familial pulmonary
arterial hypertension – FPAH and [1.3] pulmonary arte-
rial hypertension related to risk factors or associated
conditions – APAH.
Risk factors and associated conditions
A risk factor for PH is any factor or condition that is sus-
pected to play a predisposing or facilitating role in the
development of the disease. Risk factors may include
drugs and chemicals, diseases or phenotype (age, gen-
der). The term of ‘‘associated conditions’’ is used when
Table 1 Clinical classiﬁcation of pulmonary hypertension – Venice 2003
1. Pulmonary arterial hypertension (PAH)
1.1. Idiopathic (IPAH)
1.2. Familial (FPAH)
1.3. Associated with (APAH):
1.3.1. Connective tissue disease
1.3.2. Congenital systemic to pulmonary shunts
1.3.3. Portal hypertension
1.3.4. HIV infection
1.3.5. Drugs and toxins
1.3.6. Other (thyroid disorders, glycogen storage disease, Gaucher’s disease, hereditary haemorrhagic telangiectasia,
haemoglobinopathies, myeloproliferative disorders, splenectomy)
1.4. Associated with signiﬁcant venous or capillary involvement
1.4.1. Pulmonary veno-occlusive disease (PVOD)
1.4.2. Pulmonary capillary haemangiomatosis (PCH)
1.5. Persistent pulmonary hypertension of the newborn (PPHN)
2. Pulmonary hypertension associated with left heart diseases
2.1. Left-sided atrial or ventricular heart disease
2.2. Left-sided valvular heart disease
3. Pulmonary hypertension associated with lung respiratory diseases and/or hypoxia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Sleep disordered breathing
3.4. Alveolar hypoventilation disorders
3.5. Chronic exposure to high altitude
3.6. Developmental abnormalities
4. Pulmonary hypertension due to chronic thrombotic and/or embolic disease
4.1. Thromboembolic obstruction of proximal pulmonary arteries
4.2. Thromboembolic obstruction of distal pulmonary arteries
4.3. Non-thrombotic pulmonary embolism (tumour, parasites, foreign material)
5. Miscellaneous
Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels (adenopathy, tumour, ﬁbrosing mediastinitis)
2246 ESC Guidelinesa statistically signiﬁcantly increased incidence of PAH is
found with a given predisposing factor, without, how-
ever, meeting ‘‘Koch’s postulate’’ for causal relation-
ship. Since the absolute risk of known risk factors for
PAH is generally low, individual susceptibility or genetic
predisposition is likely to play an important role. During
the Evian meeting in 1998, different risk factors and
associated conditions were categorised according to
the strength of their association with PH and their prob-
able causal role. ‘‘Deﬁnite’’ indicates an association
based on several concordant observations including a
major controlled study or an unequivocal epidemic.
‘‘Very likely’’ indicates several concordant observations
(including large case series and studies) that are not
attributable to identiﬁed causes. ‘‘Possible’’ indicates
an association based on case series, registries or expert
opinions. ‘‘Unlikely’’ indicates risk factors that were sus-
pected but for which controlled studies failed to demon-
strate any association.
According to the strength of the evidence, Table 2
summarises, risk factors and associated conditions al-
ready known
19 and novel ‘‘possible’’ risk factors for
PAH that were identiﬁed recently, according to several
case series or case reports. The new possible risk factors
include haematological conditions such as asplenia sec-
ondary to surgical splenectomy,
20 sickle cell disease,
21
b-thalassaemia
22 and chronic myeloproliferative disor-
ders
23 (polycythaemia vera, essential thrombocytaemia
and myeloﬁbrosis with myeloid metaplasia accompanying
chronic myeloid leukaemia or the myelodysplastic syn-
drome). Possible risk factors include also rare genetic
or metabolic diseases such as type 1a glycogen storage
disease (Von Gierke disease),
24 Gaucher’s disease
25 and
hereditary haemorrhagic telangiectasia (Osler–Weber–
Rendu disease).
26
Pulmonary veno-occlusive disease and
pulmonary capillary haemangiomatosis
In the Evian classiﬁcation, PVOD was included in the
pulmonary venous hypertension category that consists
predominantly of left-sided heart diseases and PCH
was included in the last and heterogeneous group of
PH caused by diseases that directly affect the pulmon-
ary vasculature. The similarities in the pathological
features and clinical presentation, along with the pos-
sible occurrence of pulmonary oedema during epo-
prostenol therapy, suggest that these disorders may
overlap. Accordingly, it seems logical to include PVOD
and PCH within the same group, most appropriately
within the category of PAH. In fact, the clinical pre-
sentation of PVOD and PCH is generally similar to that
of IPAH and the risk factors or conditions associated
with PAH and PVOD/PCH are similar and include the
scleroderma spectrum of the disease, HIV infection,
and the use of anorexigens. Thus, in the new clinical
classiﬁcation (Table 1), the PAH Clinical classiﬁcation
group 1 includes another subgroup termed PAH associ-
ated with signiﬁcant venous or capillary involvement
(Clinical class 1.4).
Classiﬁcation of congenital
systemic-to-pulmonary shunts
The proposed classiﬁcation of congenital systemic-to-
pulmonary shunts takes into account the type and the
dimensions of the defect, the presence of associated
extracardiac abnormalities and the correction status (Ta-
ble 3). All these factors are relevant for the development
of PH and Eisenmenger physiology and the prognosis.
Eisenmenger syndrome can be caused by simple or
complex (about 30% of cases) congenital heart defects.
27
Table 2 Risk factors and associated conditions classiﬁed
according to the level of evidence
1. Drugs and toxins
1.1. Deﬁnite
  Aminorex
  Fenﬂuramine
  Dexfenﬂuramine
  Toxic rapeseed oil
1.2. Very likely
  Amphetamines
  L-tryptophan
1.3. Possible
  Meta-amphetamines
  Cocaine
  Chemotherapeutic agents
1.4. Unlikely
  Antidepressants
  Oral contraceptives
  Oestrogen therapy
  Cigarette smoking
2. Demographic and medical conditions
2.1. Deﬁnite
  Gender
2.2. Possible
  Pregnancy
  Systemic hypertension
2.3. Unlikely
  Obesity
3. Diseases
3.1. Deﬁnite
  HIV Infection
3.2. Very likely
  Portal hypertension/liver disease
  Connective tissue diseases
  Congenital systemic-pulmonary cardiac shunts
3.3. Possible
  Thyroid disorders
  Haematological conditions
– Asplenia secondary to surgical splenectomy
– Sickle cell disease
– b-thalassaemia
– Chronic myeloproliferative disorders
  Rare genetic or metabolic diseases
–Type 1a glycogen storage disease (Von Gierke
disease)
–Gaucher’s disease
–Hereditary haemorrhagic telangiectasia
(Osler–Weber–Rendu disease)
HIV: human immunodeﬁciency virus.
ESC Guidelines 2247Among simple defects, ventricular septal defects appear
to be the most frequent, followed by atrial septal defects
and patent ductus arteriosus.
27 It is calculated that 10% of
patients with ventricular septal defects of any size that
are older than 2 years can develop Eisenmenger syndrome
as compared to 4–6% of subjects with atrial septal de-
fects.
28,29 For patients with large defects, almost all
cases with truncus arteriosus, 50% of cases with ventricu-
lar septal defects and 10% of those with atrial septal de-
fects will develop PAH and pulmonary vascular disease.
30
In patients with atrial septal defects, those with sinus
venosus defects have an higher incidence of PAH (16%)
as compared to ostium secundum defects (4%).
31
The development of PAH with pulmonary vascular dis-
ease appears to be related to the size of the defect. In
fact, with small- to moderate-size ventricular septal de-
fects only 3% of patients develop PH.
32,33 In contrast with
largerdefects(>1.5cmindiameter),50%willbeaffected.
In case of small defects (ventricular septal defects <1 cm
and atrial septal defects <2 cm of effective diameter as-
sessed by echo) the exact pathophysiological role of the
heart defect on the development of PAH is unknown.
In some patients severe PAH can be detected after
‘‘successful’’ correction of the heart defect. In many of
thesecasesitisnotclearifirreversiblepulmonaryvascular
lesions were already present before the surgical interven-
tion or if the pulmonary vascular disease has progressed
despite a successful correction. Usually an early correc-
tion prevents the subsequent development of PAH.
Pathology of pulmonary arterial
hypertension
PAH includes various forms of PH of different aetiologies
but similar clinical presentation, and in many cases sim-
ilar response to medical treatment. Histopathological
changes in various forms of PAH are qualitatively similar
5
but with quantitative differences in the distribution and
prevalence of pathological changes in the different com-
ponents of the pulmonary vascular bed (arterioles, capil-
laries or veins). The following updated pathological
classiﬁcation has been proposed at the Third World Sym-
posium on PAH of Venice (Table 4).
6
Pulmonary arteriopathy
The main histopathological features of pulmonary arteri-
opathy include medial hypertrophy, intimal thickening,
adventitial thickening and complex lesions.
Medial hypertrophy is an increase in the cross sec-
tional area of the media of pre and intra-acinar pulmon-
ary arteries. It is due to both hypertrophy and
hyperplasia of smooth muscle ﬁbers as well as increase
in connective tissue matrix and elastic ﬁbers in the med-
ia of muscular arteries.
Intimal thickening may be concentric laminar, eccen-
tric or concentric non-laminar. Ultrastructurally and im-
muno-histochemically the intimal cells show features of
ﬁbroblasts, myoﬁbroblasts and smooth muscle cells.
Adventitial thickening occurs in most cases of PAH
but it is more difﬁcult to evaluate.
Complex lesions. The plexiform lesion is a focal prolif-
eration of endothelial channels lined by myoﬁbroblasts,
smooth muscle cells and connective tissue matrix. These
lesions are at an arterial branching point or at the origin
of a supernumerary artery, distally to marked oblitera-
tive intimal thickening of the parent artery. The fre-
quency of the plexiform lesions in PAH remains
undetermined. Arteritis may be associated with plexi-
form lesions and it is characterised by a necrosis of the
arterial wall with ﬁbrinoid insudation and inﬁltration
with inﬂammatory cells.
All the above changes are seen typically in clinical
classiﬁcation (Table 1) groups 1.1 (IPAH), 1.2 (FPAH)
and 1.3 (APAH).
Pulmonary occlusive venopathy (also called
pulmonary veno-occlusive disease)
Pulmonary occlusive venopathy accounts for a relatively
small proportion of cases of PH; main histo-pathological
features consist of extensive and diffuse occlusion of pul-
monary venules and veins of various sizes. The luminal
occlusion can be either solid or eccentric. In addition,
the media may be thickened. In pulmonary occlusive ven-
opathy, large amounts of haemosiderin are found both
within the cytoplasm of alveolar macrophages and type
II pneumocytes, as well as deposits in the interstitium.
The capillary vessels are engorged and prominent and
they may be so tortuous as to mimic pulmonary capillary
haemangiomatosis. Pulmonary arterioles can show
remodelling with medial hypertrophy and intimal ﬁbro-
sis. Plexiform lesions and ﬁbrinoid arteritis are not de-
scribed in pulmonary occlusive venopathy. The
pulmonary interstitium frequently shows oedema in the
Table 3 Classiﬁcation of congenital systemic-to-pulmonary
shunts
1. Type
Simple
Atrial septal defect (ASD)
Ventricular septal defect (VSD)
Patent ductus arteriosus
Total or partial unobstructed anomalous pulmonary venous
return
Combined
Describe combination and deﬁne prevalent defect if any
Complex
Truncus arteriosus
Single ventricle with unobstructed pulmonary blood ﬂow
Atrioventricular septal defects
2. Dimensions
Small (ASD 6 2.0 cm and VSD 6 1.0 cm)
Large (ASD > 2.0 cm and VSD > 1.0 cm)
3. Associated extracardiac abnormalities
4. Correction status
Non-corrected
Partially corrected (age)
Corrected: spontaneously or surgically (age)
2248 ESC Guidelineslobular septa, which may progress to interstitial ﬁbrosis.
Lymphatics within the lung and pleura are also dilated.
These changes are seen typically in clinical classiﬁcation
(Table 1) group 1.4.1 (PVOD).
Pulmonary microvasculopathy (also called
pulmonary capillary haemangiomatosis)
Pulmonary microvasculopathy is another rare condition
characterised by localised capillary proliferation within
the lung. The distribution of pulmonary microvasculopa-
thy is usually panlobar and patchy. The abnormal prolif-
erating capillaries inﬁltrate the walls of arteries and
veins invading muscular walls and occluding the lumen.
In the areas of capillary proliferation, pulmonary haemo-
siderosis, characterised by haemosiderin-laden macro-
phages and type II pneumocytes, is also present.
Similar to pulmonary occlusive venopathy, the pulmon-
ary arteries in pulmonary microvasculopathy show
marked muscular hypertrophy and intimal thickening.
These changes are seen typically in clinical classiﬁcation
(Table 1) group 1.4.2 (PCH).
Finally, there are unclassiﬁable conditions with atyp-
ical histopathological features or inadequate sampling
of blood vessels.
Pathogenesis of pulmonary arterial
hypertension
The exact processes that initiate the pathological
changes seen in PAH are still unknown even if we now
understand more of the mechanisms involved. It is recog-
nised that PAH has a multi-factorial pathobiology that in-
volves various biochemical pathways and cell types. The
increase of PVR is related to different mechanisms
including vasoconstriction, obstructive remodelling of
the pulmonary vessel wall, inﬂammation and thrombosis.
Pulmonary vasoconstriction is believed to be an early
component of the pulmonary hypertensive process.
34
Excessive vasoconstriction has been related to abnormal
function or expression of potassium channels in the
smooth muscle cells
35 and to endothelial dysfunction.
10
Reduced plasma levels of a vasodilator and antiprolifera-
tive substance such as Vasoactive Intestinal Peptide has
been shown in patients with PAH.
36
Endothelial dysfunction leads to chronically impaired
production of vasodilators such as nitric oxide (NO) and
prostacyclin along with overexpression of vasoconstric-
tors such as thromboxane A2 (TxA2) and endothelin-1
(ET-1).
10 Many of these abnormalities both elevate vas-
cular tone and promote vascular remodelling.
The process of pulmonary vascular remodelling in-
volves all layers of the vessel wall and is characterised
by proliferative and obstructive changes that involve sev-
eral cell types including endothelial, smooth muscle and
ﬁbroblasts.
6,7 In addition, in the adventitia there is in-
creased production of extracellular matrix including
collagen, elastin, ﬁbronectin, and tenascin.
37 Angiopoie-
tin-1, an angiogenic factor essential for vascular lung
development, seems to be upregulated in cases of PH
correlating directly with the severity of the disease.
38
Also inﬂammatory cells and platelets may play a sig-
niﬁcant role in PAH. In fact, inﬂammatory cells are ubiq-
uitous in PAH pathological changes and pro-inﬂammatory
cytokines are elevated in the plasma of PAH patients.
39
Alterations in the metabolic pathways of serotonin, a
pulmonary vasoconstrictor substance stored in platelets,
have also been detected in PAH patients.
40
Prothrombotic abnormalities have been demonstrated
in PAH patients
41 and thrombi are present in both micro-
circulation and elastic pulmonary arteries.
6 In fact, ﬁbri-
nopeptide A levels that reﬂect thrombin activity,
42 and
TxA2 levels,
43 are both elevated in patients with IPAH.
Despite the identiﬁcation of mutations in the BMPR2
in the majority of cases of familial PAH,
8,9 the pathobio-
logical links between this genetic abnormality and the
development of pulmonary vascular hypertensive disease
Table 4 Pathological classiﬁcation of vasculopathies of pulmonary hypertension
(1) Pulmonary arteriopathy
a (pre-and intra-acinar arteries)
Subsets
 Pulmonary arteriopathy with isolated medial hypertrophy
 Pulmonary arteriopathy with medial hypertrophy and intimal thickening (cellular, ﬁbrotic)
– Concentric laminar
– Eccentric, concentric non-laminar
 Pulmonary arteriopathy with plexiform and/or dilatation lesions or arteritis
 Pulmonary arteriopathy with isolated arteritis
(1a) As above but with coexisting venous-venular changes
a (cellular and/or ﬁbrotic intimal thickening, muscularisation)
(2) Pulmonary occlusive venopathy
b (veins of various size and venules) with or without coexisting arteriopathy
(3) Pulmonary microvasculopathy
c with or without coexisting arteriopathy and/or venopathy
(4) Unclassiﬁable
Atypical histopathological features or inadequate sampling of blood vessels
a These changes are seen typically in clinical classiﬁcation (Table 1) groups 1.1 (idiopathic pulmonary arterial hypertension), 1.2 (familial
pulmonary arterial hypertension) and 1.3 (associated pulmonary arterial hypertension).
b These changes are seen typically in clinical classiﬁcation (Table 1) group 1.4.1 (pulmonary venoocclusive disease).
c These changes are seen typically in clinical classiﬁcation (Table 1) group 1.4.2 (pulmonary capillary haemangiomatosis).
ESC Guidelines 2249have not been clariﬁed. On the other hand, the high fre-
quency of ‘‘true’’ sporadic IPAH cases and reduced pen-
etrance of familial PAH (only 20% of BMPR2 gene
mutation carriers manifest the disease), suggests that
additional triggers are required for the development of
the condition. Mechanisms could be second somatic
mutations within an unstable BMPR-2 pathway,
44 poly-
morphisms for genes related to PAH [serotonin trans-
porter gene (5HTT),
40 nitric oxide synthase (ec-NOS)
gene
45 and carbamyl-phosphate synthase (CPS) gene
46]
or any stimulus able to disrupt pulmonary vascular cells
growth control. In addition there may be further genes,
possibly related to the BMP/TGF-bv pathway, to be iden-
tiﬁed. Indeed, mutations in the TGF-bv receptors, acti-
vin-receptor-like kinase 1 (ALK-1) and endoglin, have
been identiﬁed in PAH patients with a personal or family
history of hereditary haemorrhagic telangiectasia, i.e.
Osler–Weber–Rendu.
26,47
Even if many pathobiological mechanisms have been
identiﬁed in the cells and tissues of PAH patients, the ex-
act interactions between these mechanisms in initiating
and progressing the pathological processes are not well
understood. Possible theoretical pathways (Fig. 1) in-
clude the classical interaction between genetic predispo-
sition and risk factors that may induce changes in
different cell types (smooth muscle cells, endothelial
cells, inﬂammatory cells, platelets) and in the extracel-
lular matrix of pulmonary microcirculation. The
imbalance between thrombogenic, mitogenic, proinﬂam-
matory and vasoconstrictive factors as opposed to
anticoagulant, antimitotic and vasodilating mechanisms
may initiate and perpetuate interacting processes such
as vasoconstriction, proliferation, thrombosis and
inﬂammation in the lung microcirculation. These mecha-
nisms are responsible for the initiation and progression of
pathological obstructive changes typical of PAH. The
consequent increase of PVR leads to right ventricular
overload and eventually to right ventricular failure and
death.
Future studies are required to ﬁnd which, if any, of
these abnormalities initiates PAH and which are best tar-
geted to cure the disease.
Diagnostic strategy
The diagnostic process of PH requires a series of investi-
gations that are intended to make the diagnosis, to clar-
ify the clinical class of PH and the type of PAH and to
evaluate the functional and haemodynamic impairment.
For practical purposes it can be useful to adopt a sequen-
tial approach that includes four stages (Fig. 2):
I. Clinical suspicion of pulmonary hypertension
II. Detection of pulmonary hypertension
III. Pulmonary hypertension clinical class identiﬁcation
IV. Pulmonary arterial hypertension evaluation (type,
functional capacity, haemodynamics)
BMPR-2 mutations
ALK1 mutations
5HTT polymorphism
ec-NOS polymorphism
CPS polymorphism
Etc.
Genetic Predisposition
Anorexigens
HIV infection
Increased Pulmonary Flow
Portal Hypertension
Connective Tissue Diseases
Etc.
Risk Factors
Proliferation
Thrombosis Inflammation
Pulmonary Vascular Damage
Endothelial Dysfunction Smooth Muscle Cells
Dysfunction
Matrix Changes, Platelets
and Inflammatory Cells
Activation
Pulmonary Hypertensive Vascular Disease
Initiation and Progression
Vasoconstriction
Fig. 1 Pulmonary arterial hypertension: potential pathogenetic and pathobiologic mechanisms. BMPR-2: bone morphogenetic receptor protein 2 gene;
ALK 1: activin-receptor-like kinase 1 gene; 5-HTT: serotonin transporter gene; ec-NOS: nitric oxide synthase gene; CPS: carbamyl-phosphate synthetase
gene.
2250 ESC GuidelinesClinical suspicion of pulmonary hypertension
The clinical suspicion of PH should arise in any case of
breathlessness without overt signs of speciﬁc heart or
lung disease or in patients with underlying lung or heart
disease whenever there is increasing dyspnoea unex-
plained by the underlying disease itself. The symptoms
of PH
48 can also include fatigue, weakness, angina, syn-
cope, and abdominal distension. Symptoms at rest are
reported only in very advanced cases.
The physical signs of PH
48 may require experience to
be appreciated. They include left parasternal lift, accen-
tuated pulmonary component of S2, pansystolic murmur
of tricuspid regurgitation, diastolic murmur of pulmonary
insufﬁciency and right ventricular S3. Jugular vein disten-
sion, hepatomegaly, peripheral oedema, ascites and cool
extremities characterise patients in a more advanced
state with right ventricular failure at rest. Central cyano-
sis (and sometime peripheral cyanosis and mixed forms)
may also be present. Lung sounds are usually normal.
The clinical suspicion is raised when symptoms and
signs are present in subjects with conditions that can
be associated with PAH such as CTD, portal hypertension,
HIV infection and congenital heart diseases with sys-
temic-to-pulmonary shunts. In the presence of these pre-
disposing abnormalities some experts support a rationale
for periodic screening assessments to identify asymptom-
atic patients in the early stage of PH
49 (see Speciﬁc Con-
ditions below).
Finally, PH can be suspected when abnormal electro-
cardiographic, chest radiograph or echocardiographic
ﬁndings, are detected in the course of procedures per-
formed for other clinical reasons.
Detection of pulmonary hypertension
The detection phase requires investigations that are able
to conﬁrm the diagnosis of PH. They include the electro-
cardiogram (ECG), the chest radiograph and transtho-
racic Doppler-echocardiography.
ECG
The ECG may provide suggestive or supportive evidence
of PH by demonstrating right ventricular hypertrophy
and strain, and right atrial dilation. Right ventricular
hypertrophy on ECG is present in 87% and right axis devi-
ation in 79% of patients with IPAH.
48 However, the ECG
has inadequate sensitivity (55%) and speciﬁcity (70%) to
be a screening tool for detecting signiﬁcant PAH.
50 A nor-
mal ECG does not exclude the presence of severe PH.
Chest radiograph
In 90% of IPAH patients the chest radiograph is abnormal
at the time of diagnosis.
48 Findings include central pul-
monary arterial dilatation which contrasts with ‘pruning’
(loss) of the peripheral blood vessels. Right atrial and
ventricular enlargement may be seen and it progresses
in more advanced cases. The chest radiograph allows
associated moderate-to-severe lung disease or pulmon-
ary venous hypertension due to left heart abnormalities
to be reasonably excluded. However, a normal chest
radiograph does not exclude mild post capillary pulmon-
ary hypertension including left-heart disease or pulmon-
ary veno-occlusive disease.
Transthoracic Doppler-echocardiography
Transthoracic Doppler-echocardiography (TTE) is an
excellent non-invasive screening test for the patient with
suspected PH. TTE estimates pulmonary artery systolic
pressure (PASP) and can provide additional information
about the cause and consequences of PH. PASP is equiv-
alent to right ventricular systolic pressure (RVSP) in the
absence of pulmonary outﬂow obstruction. RVSP is esti-
mated by measurement of the systolic regurgitant tricus-
pid ﬂow velocity v and an estimate of right atrial
pressure (RAP) applied in the formula: RVSP = 4v
2 + RAP.
RAP is either a standardised value, or estimated value
from characteristics of the inferior vena cava
51 or from
jugular venous distension. Tricuspid regurgitant jets
can be assessed in the majority (74%) of patients with
PH.
52 Most studies report a high correlation (0.57–0.93)
between TTE and right heart catheterisation (RHC) mea-
surements of PASP.
53 However, in order to minimise false
positives
54 it is important to identify speciﬁc values for
the deﬁnition of PH as assessed by TTE.
The range of RVSP among healthy controls has been
well characterised. Among a broad population of male
and female subjects ranging from 1 to 89 years old, RVSP
was reported as 28 ± 5 mmHg (range 15–57 mmHg). RVSP
increases with age and body mass index.
55 According to
these data mild PH can be deﬁned as a PASP of approxi-
mately 36–50 mmHg or a resting tricuspid regurgitant
velocity of 2.8–3.4 m/s (assuming a normal RAP of 5
mmHg). It should be noted that also with this deﬁnition
a number of false positive diagnoses can be anticipated
especially in aged subjects and conﬁrmation with RHC
is required in symptomatic patients (NYHA class II–III).
In asymptomatic subjects (NYHA class I) a concomitant
CTD should be excluded and echocardiography should
be repeated in six months. It should be noted that deﬁn-
ing the level for an elevated RVSP does not deﬁne the
II. PH Detection
III. PH Class Identification
IV. PAH Evaluation: Type
Exercise Capacity
Haemodynamics
I. PH Suspicion
ECG 
Chest Radiograph
TT Echocardiography
Pulmonary Function Tests & ABG
Ventilation/Perfusion Lung Scan
High Resolution CT
Spiral CT
Pulmonary Angiography
Blood tests & Immunology
HIV test
Abdominal Ultrasound Scan
6 min Walk Test, Peak VO2
Right Heart Cath + Vasoreactivity
Symptoms & Physical Examination
Screening Procedures
Incidental Findings
Fig. 2 Pulmonary hypertension diagnostic approach. ABG: arterial blood
gases; CT: computerised tomography; PH: pulmonary hypertension; PAH:
pulmonary arterial hypertension; TT: transthoracic; VO2: oxygen con-
sumption; Cath: catheterisation.
ESC Guidelines 2251point at which an increased RVSP is clinically important,
is predictive of future consequences and/or requires spe-
ciﬁc treatments. Also the possibility of false negative
Doppler-echocardiographic results should be considered
in case of high clinical suspicion.
56
Additional echocardiographic and Doppler parameters
are important for diagnosis conﬁrmation and assessment
of severity of PH including right and left ventricular
dimensions and function, tricuspid, pulmonary and mitral
valve abnormalities, right ventricular ejection and left
ventricular ﬁlling characteristics, inferior vena cava
dimensions and pericardial effusion size.
57,58
Besides identiﬁcation of PH, TTE also allows a differ-
ential diagnosis of possible causes and virtually starts the
phases III and IV of the diagnostic process. TTE can rec-
ognise left heart valvular and myocardial diseases
responsible for pulmonary venous hypertension (Clinical
Class 2), and congenital heart diseases with systemic-
to-pulmonary shunts can be easily identiﬁed (Clinical
Class 1.3.2). The venous injection of agitated saline as
contrast medium can help the identiﬁcation of patent
foramen ovale or small sinus venosus type atrial septal
defects that can be overlooked on the standard TTE
examination. Trans-oesophageal echocardiography
(TEE) is rarely required and is usually used to conﬁrm
the presence, and assess the exact size, of small atrial
septal defects.
Pulmonary hypertension clinical class
identiﬁcation
The next step after the detection of PH is the identiﬁca-
tion of the Clinical Class according to the clinical classi-
ﬁcation of Venice (Table 1).
1 This is accomplished by the
use of essential tests such as TTE (as speciﬁed above),
pulmonary function tests (PFT) (including arterial blood
gas sample) and ventilation and perfusion (V/Q) lung
scan. If required, in particular circumstances additional
tests can be performed such as chest high resolution CT
(HRCT), spiral CT and pulmonary angiography.
Pulmonary function tests and arterial blood gases
PFTs and arterial blood gas sampling can identify the
contribution of underlying airway or parenchymal lung
disease. Patients with PAH usually have decreased lung
diffusion capacity for carbon monoxide (DLCO) [typically
in the range of 40–80% predicted] and mild to moderate
reduction of lung volumes. The arterial oxygen tension
(PaO2) is normal or only slightly lower than normal and
arterial carbon dioxide tension (PaCO2) is decreased as
a result of alveolar hyperventilation. Chronic obstructive
pulmonary disease as a cause of hypoxic PH, is diagnosed
on the evidence of irreversible airﬂow obstruction,
59
usually by measuring the forced expired volume in one
second (FEV1). These patients often have a normal or in-
creased PaCO2 together with airﬂow limitation and in-
creased residual volumes and reduced DLCO.
Emphysema is now diagnosed using HRCT. A decrease in
lung volume together with a decrease in DLCO may indi-
cate a diagnosis of interstitial lung disease (ILD). Again
the HRCT is the principle way of assessing the severity
of ILD.
60 If clinically suspected, screening overnight
oximetry and polisomnography will exclude signiﬁcant
obstructive sleep apnoea/hypopnoea and nocturnal
desaturation.
Ventilation and perfusion (V/Q) lung scan
In PAH the lung V/Q scans may be entirely normal. How-
ever, they may also show small peripheral non-segmental
defects in perfusion. These are normally ventilated and
thus represent V/Q mismatch. Lung V/Q scan provides
a means of diagnosis of chronic thromboembolic pulmon-
ary hypertension (CTEPH, Clinical Class 4).
61 In CTEPH
the perfusion defects are usually found in lobar and seg-
mental regions leading to segmental defects in the perfu-
sion image. As these areas are normally ventilated, the
perfusion defects are described as being unmatched by
ventilation defects. V/Q scanning showed sensitivity of
90–100% with speciﬁcity of 94–100% for distinguishing
between IPAH and CTEPH.
61 A caveat is that unmatched
perfusion defects are also seen in veno-occlusive dis-
ease. Such a patient requires careful further investiga-
tion (see section on HRCT). In patients with
parenchymal lung disease the perfusion defects are
matched by ventilation defects.
High resolution CT of the lung
HRCT provides detailed views of the lung parenchyma
and facilitates the diagnosis of ILD and emphysema.
The presence of interstitial markings similar to those
seen with advanced left ventricular failure such as dif-
fuse central ground-glass opaciﬁcation and thickening
of interolobular septa suggest pulmonary veno-occlusive
disease; additional ﬁndings are lymphadenopathy, pleu-
ral shadows and effusions.
62 Diffuse bilateral thickening
of the interlobular septae and the presence of small,
centrilobular, poorly circumscribed nodular opacities
suggest pulmonary capillary haemangiomatosis.
Contrast enhanced spiral CT of the lung, pulmonary
angiography and magnetic resonance imaging
Contrast-enhanced spiral (or helical) CT is indicated in
pulmonary hypertensive patients when the V/Q lung scin-
tigraphy shows segmental or sub-segmental defects of
perfusion with normal ventilation, i.e. evidence of a V/
Q mismatch and may demonstrate central chronic pul-
monary thromboemboli. CT features of chronic thrombo-
embolic disease are complete occlusion of pulmonary
arteries, eccentric ﬁlling defects consistent with throm-
bi, recanalisation, and stenoses or webs.
63,64
Traditional pulmonary angiography is still required in
the work-up of CTEPH to better identify patients that
can beneﬁt from the intervention of endarterectomy.
61
Pulmonary angiography is more accurate in the identiﬁ-
cation of distal obstructions and it is indicated also in
cases of inconclusive contrast-enhanced spiral CT in pa-
tients with clinical and lung scintigraphy suspicion of
CTEPH. This procedure can be safely performed by expe-
rienced staff in patients with severe PH. Useful technical
details include the utilisation of modern contrast media,
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ple views.
Magnetic resonance imaging is increasingly used in pa-
tients with PAH for the evaluation of pathological and
functional changes of both heart and pulmonary circula-
tion.
63 However, additional experience is needed before
introducing this tool in the routine assessment of pa-
tients with PAH.
Pulmonary arterial hypertension evaluation
(type, exercise capacity, haemodynamics)
When the Clinical Class of PAH (Clinical Class 1) has been
determined, additional investigations may be required
for the exact identiﬁcation of the type of PAH and for
the assessment of exercise capacity and haemodynamics.
Blood tests and immunology
Routine biochemistry, haematology and thyroid function
tests are required. Thrombophilia screen should be per-
formed including antiphospholipid antibodies (lupus anti-
coagulant, anticardiolipin antibodies). CTD are
diagnosed primarily on clinical and laboratory criteria
and an autoimmune screen consists of antinuclear anti-
bodies (ANA), including anti-centromere antibody, anti-
SCL70 and RNP. About one third of patients with IPAH
have positive but low antinuclear antibody titre (61:80
dilutions).
65 Patients with a substantially elevated ANA
and/or suspicious clinical features require further sero-
logical assessment and rheumatology consultation. Final-
ly, all patients should be consented for and undertake a
HIV serology test.
Abdominal ultrasound scan
Liver cirrhosis and/or portal hypertension can be reliably
excluded by the use of abdominal ultrasound scan. The
colour-Doppler examination also allows the differentia-
tion between passive portal hypertension, due to right
heart failure, from portal hypertension caused by an in-
crease in the trans-hepatic venous gradient associated
with liver cirrhosis. The use of contrast agents may im-
prove the diagnosis.
66 Portal hypertension can be con-
ﬁrmed by the detection of an increased gradient
between free and occluded (wedge) hepatic vein pres-
sure at the time of RHC (see Porto-pulmonary
hypertension).
67
Exercise capacity
The objective assessment of exercise capacity in pa-
tients with PAH is an important instrument for evaluating
disease severity
68,69 and treatment effect.
70,71 The most
commonly used exercise tests for PH are the six-minute
walk test and cardiopulmonary exercise testing with
gas exchange measurement.
The six-minute walk test (6MWT) is technically simple
and inexpensive.
72 It is predictive of survival in IPAH and
also correlates inversely with NYHA functional status
severity.
68 6MWT is usually combined with the Borg score
that assesses the subjective level of dyspnoea with the
exercise. Reduction of arterial oxygen saturation >10%
during 6MWT increases mortality risk 2.9 times over a
median follow-up of 26 months.
73 6MWT is the traditional
‘‘primary’’ end point for the great majority of controlled
clinical trials performed in PAH.
70
Cardiopulmonary exercise testing (CPET) allows
measurement of ventilation and pulmonary gas exchange
during exercise testing providing additional ‘‘pathophys-
iologic’’ information to that derived from standard exer-
cise testing. PAH patients show reduced peak VO2,
reduced peak work rate, reduced ratio of VO2 increase
to work rate increase, reduced anaerobic threshold and
reduced peak oxygen pulse; they show also increased
VE and VCO2 slope representative of ventilatory inefﬁ-
ciency.
69 Peak VO2 is correlated with the prognosis of
PAH patients.
69
CPET has been used in recent multicentre trials but it
failed to conﬁrm improvements observed with
6MWT.
74,75 A possible explanation for these ﬁndings is
that CPET is technically more difﬁcult than 6MWT and
its results may be inﬂuenced by the experience of the
centres. An alternative explanation may relate to a lack
of sensitivity of CPET in measuring response to treatment
which has less effect on maximal as opposed to submax-
imal exercise.
Haemodynamics
RHC is required to conﬁrm the diagnosis of PAH, to assess
the severity of the haemodynamic impairment and to
test the vasoreactivity of the pulmonary circulation.
The following parameters should always be assessed:
heart rate, RAP, PAP (systolic, diastolic and mean), pul-
monary capillary wedge pressure (PWP), cardiac output
(by thermodilution, or the Fick method in cases of sys-
temic-to-pulmonary shunts), blood pressure, pulmonary
and systemic vascular resistance, arterial and mixed ve-
nous oxygen saturation (and superior vena cava satura-
tion in cases of systemic-to-pulmonary shunts).
PAH is deﬁned by a mean PAP >25 mmHg at rest or >30
mmHg with exercise, by a PWP 615 mmHg and by PVR >3
mmHg/l/min (Wood units). Left heart catheterisation is
required in the rare circumstances in which a reliable
PWP cannot be measured.
Conﬁrmation of diagnosis by RHC is required in cases
of symptomatic patients (NYHA class II and III) with mild
PH as assessed by Doppler echocardiography (see above
for deﬁnition) to identify subjects needing further diag-
nostic and therapeutic procedures. The assessment of
PWP may allow the distinction between arterial and ve-
nous PH in patients with concomitant left heart diseases.
RHC is important also in patients with deﬁnite moder-
ate-to-severe PAH because the haemodynamic variables
have prognostic relevance.
2
Elevated mean RAP, mean PAP and reduced cardiac
output and central venous O2 saturation identify IPAH pa-
tients with the worst prognosis. Haemodynamic measure-
ments have been used to estimate the natural history of
IPAH in an individual patient by the use of a prediction
equation
2 that has also been utilised for assessing the
long-term effects of new treatments on survival.
76–78
However, this formula has been derived by patients on
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ago that may not represent an appropriate ‘‘control’’
group for current PAH populations.
Uncontrolled studies have suggested that long-term
administration of calcium-channel blockers (CCB) pro-
longs survival in the rare case of acutely responsive pa-
tients compared with unresponsive patients.
79 It is
generally accepted that patients who may beneﬁt from
long-term CCB can be identiﬁed by an acute vasodilator
challenge performed during RHC.
80 However, it has been
proposed that the deﬁnitive recognition of patients who
beneﬁt from CCB treatment requires both (1) the demon-
stration of a positive acute vasoreactive response and (2)
the conﬁrmation of a sustained response to long term
treatment to CCB.
81
Acute vasodilator testing should only be done using
short-acting pulmonary vasodilators at the time of the
initial RHC in experienced centres to minimise the poten-
tial risks.
82 Currently the agents used in acute testing are
intravenous (iv) prostacyclin or adenosine and inhaled ni-
tric oxide.
83,84 Half-lives, dose ranges, increments and
duration of administration for these compounds are pro-
vided in Table 5.
A positive acute vasoreactive response (positive acute
responders) is deﬁned as a reduction of mean PAP P10
mmHg to reach an absolute value of mean PAP 640
mmHg with an increase or unchanged cardiac out-
put.
11,81,85 Generally, only about 10–15% of IPAH will
meet these criteria.
81,83 Positive acute responders are
most likely to show a sustained response to long-term
treatment with high doses of CCB and are the only pa-
tients that can safely be treated with this type of ther-
apy. An empiric treatment with CCB without acute
vasoreactivity test is strongly discouraged due to possible
severe adverse effects.
Positive long-term responders to high dose CCB treat-
ment are deﬁned as patients being in NYHA functional
class I or II with near normal haemodynamics after sev-
eral months of treatment with CCB alone. Only about a
half of IPAH positive acute responders are also positive
long-term responders
81 to CCB and only in these
cases the continuation of CCB as single treatment is
warranted.
The usefulness of acute vasoreactivity tests and long-
term treatment with CCB in patients with PAH associated
with underlying processes, such as CTD or congenital
heart disease, is less clear as compared to IPAH.
81,86
However, experts suggest also in these cases to test pa-
tients for acute vasoreactivity and to look for a long-
term response to CCB in appropriate subjects.
Lung biopsy
Open or thoracoscopic lung biopsy entails substantial
risks of morbidity and mortality. Because of the low like-
lihood of altering the diagnosis and treatment, routine
biopsy is discouraged.
Assessment of severity
Several variables have been shown to predict prognosis in
IPAH when assessed at baseline or after targeted treat-
ments.
71 Very little information is available in other con-
ditions such as PAH associated with CTD, congenital
systemic to pulmonary shunts, HIV infection or portal
hypertension. In these circumstances, additional factors
may contribute to the overall outcome. In fact, PAH
associated with CTD disorders has a worse prognosis than
IPAH patients, whereas patients with PAH associated
with congenital systemic-to-pulmonary shunts have a
more slowly progressive course than IPAH patients.
In practice, the prognostic value of a single variable in
the individual patient may be less than the value of mul-
tiple concordant variables (Table 6).
Clinical variables
Among clinical variables, baseline NYHA functional clas-
siﬁcation has a deﬁnite prognostic predictive value in pa-
tients with IPAH on conventional treatment.
2 This
predictive value is conserved when NYHA classiﬁcation
is assessed either before or 3 months after the initiation
of epoprostenol treatment.
77,87 History of right heart
failure before the initiation of epoprostenol treatment
has a negative predictive value.
87 The World Health
Organisation (WHO) classiﬁcation proposed in Evian is
an adaptation of the NYHA system for PAH and many
clinicians refer to both classiﬁcations which are
nearly identical as NYHA/WHO functional classiﬁcation
(Table 7).
11,12
Exercise capacity
Several authors have shown that the 6MWT is of great
prognostic value in PAH: Miyamoto et al.
68 showed that
Table 5 Route of administration, half-lives, dose ranges, increments and duration of administration of the most used substances
on pulmonary vasoreactivity tests
Drug Route Half-life Dose range
a Increments
b Duration
c
Epoprostenol Intravenous 3 min 2–12 ng/kg/min 2 ng/kg/min 10 min
Adenosine Intravenous 5–10 s 50–350 lg/kg/min 50 lg/kg/min 2 min
Nitric oxide Inhaled 15–30 s 10–20 ppm – 5 min
d
a Initial dose and maximal dose suggested.
b Increments of dose by each step.
c Duration of administration on each step.
d For NO a single step within the dose range is suggested.
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icantly lower survival rate than those walking farther.
In another study it has been calculated that there is an
18% reduction in the risk of death per additional 50 m
walked in patients with IPAH.
73 Preliminary data show
also that arterial oxygen desaturation >10% during
6MWT increases mortality risk 2.9 times over a median
follow-up of 26 months.
73 Patients in NYHA functional
class III or IV walking 6250 m before the initiation of epo-
prostenol or <380 m after three months of epoprostenol
treatment portend a worst prognosis as compared to pa-
tients walking farther.
87 Absolute change of 6MWT dis-
tance with epoprostenol has not been found to be of
prognostic value.
Peak VO2 <10.4 ml/kg/min as assessed by CPET is cor-
related with a worse prognosis in PAH patients.
69
Echocardiographic parameters
The presence and size of a pericardial effusion as as-
sessed by TTE has a clear prognostic relevance in pa-
tients with IPAH.
88,89 In addition, right atrial size and
left ventricular eccentricity index are predictive of the
outcome of IPAH subjects.
89
Doppler right ventricular
90 index, i.e. Tei index, is a
variable which assesses both systolic and diastolic func-
tion of the right ventricle and has been found to have
prognostic relevance in PAH.
91
Haemodynamics
Elevated mean RAP and PAP at baseline, as well as re-
duced cardiac output and central venous O2 saturation,
identify IPAH patients with a worst prognosis.
2 Patients
with a positive acute response to vasoreactivity tests
have a better prognosis when compared to non-
responders.
79,83,92
On univariate analysis, the baseline haemodynamic
variables associated with a poor outcome in IPAH pa-
tients subsequently treated with epoprostenol are re-
ported to be RAP >12 mmHg, and mean pulmonary
artery pressure <65 mmHg
87 even if this last ﬁnding has
not been conﬁrmed by other series.
77 After 3 months of
epoprostenol, a fall in PVR <30% relative to baseline is as-
sociated with a poor prognosis.
87
Blood tests
Hyperuricaemia occurs with high frequency in patients
with PH and correlates with haemodynamic abnormali-
ties, e.g. elevated RAP and increased mortality in IPAH.
93
Brain natriuretic peptide is elevated in right ventricular
pressure overload and correlates with severity of right
ventricular dysfunction and mortality in PAH.
94
Additional neurohormonal plasma levels correlate
with survival e.g. norepinephrine
95 and ET-1.
96 Recently
troponin
97 levels both at baseline and after targeted
Table 6 Prognostic parameters in patients with idiopathic
pulmonary arterial hypertension
Clinical parameters
NYHA functional classiﬁcation
NYHA functional class on chronic epoprostenol treatment
History of right heart failure
Exercise capacity
6MWT distance
6MWT distance on chronic epoprostenol treatment
Peak VO2
Echocardiographic parameters
Pericardial effusion
Right atrial size
Left ventricular eccentricity index
Doppler right ventricular (Tei) index
Hemodynamics
Right atrial pressure
Mean PAP
Cardiac output
Mixed venous O2 saturation
Positive acute response to vasoreactivity tests
Fall in pulmonary vascular resistance <30% after 3 months
of epoprostenol
Blood tests
Hyperuricaemia
Baseline Brain natriuretic peptide
Brain natriuretic peptide after 3 months therapy
Troponin – detectable, especially persistent leakage
Plasma norepinephrine
Plasma endothelin-1
6MWT: six-minute walk test; NYHA: New York Heart Association.
Table 7 NYHA/WHO Classiﬁcation of functional status of patients with pulmonary hypertension
11,12
Class Description
I Patients with pulmonary hypertension in whom there is no limitation of usual physical activity; ordinary physical activity
does not cause increased dyspnoea, fatigue, chest pain or pre-syncope.
II Patients with pulmonary hypertension who have mild limitation of physical activity. There is no discomfort at rest, but
normal physical activity causes increased dyspnoea, fatigue, chest pain or pre-syncope.
III Patients with pulmonary hypertension who have a marked limitation of physical activity. There is no discomfort at rest,
but less than ordinary activity causes increased dyspnoea, fatigue, chest pain or pre-syncope.
IV Patients with pulmonary hypertension who are unable to perform any physical activity and who may have signs of right
ventricular failure at rest. Dyspnoea and/or fatigue may be present at rest and symptoms are increased by almost any
physical activity.
ESC Guidelines 2255treatments have been found to have prognostic rele-
vance in PAH patients.
Treatment
The treatment of PAH has been traditionally character-
ised by few and difﬁcult options.
98 Recently, we have
faced a dramatic change from the slow progress in the
past decades to the remarkable number of randomised
controlled trials (RCT) accomplished in the last few
years. However we have also inherited different treat-
ments that are generally accepted to be efﬁcacious
(e.g. oral anticoagulants, oxygen, CCBs), although not
supported by RCT and not formally approved by Regula-
tory Agencies for the speciﬁc PAH indication.
The objective of this section is to review each form of
therapy according to the Level of Evidence classiﬁcation
as suggested by the Committee for Practice Guidelines of
the European Society of Cardiology.
16 In addition, we will
provide the Grade of Recommendation
16 that will take
into account the clinical efﬁcacy of treatments that,
for different reasons, have not been tested in RCTs such
as oral anticoagulants, oxygen, CCBs, balloon atrial sep-
tostomy and/or lung transplantation. Furthermore, we
will provide information concerning current country-
speciﬁc regulatory approval and labelling for each
compound. Finally, we will propose an evidence-based
treatment algorithm
85 that is intended to provide a guide
to the selective use of each form of therapy.
Introduction to level of evidence and grade of
recommendation
The grading system for the Level of Evidence is substan-
tially based on the number of favourable RCTs performed
with a given treatment strategy
16 (Table 8) and has been
adapted to the speciﬁc requirements of a rare disease.
The only difference is that we did not include in category
B ‘‘non-randomised studies’’ because all these studies in
PAH are rather small therefore they are included in cat-
egory C. In category B we included the wording ‘‘multi-
ple randomised clinical trials with heterogeneous
results’’ because this situation may happen (and has hap-
pened) and this deﬁnition is more comprehensive even if
the ﬁnal result is that ‘‘a single randomised clinical
trial’’ resulted positive. The analysis takes into consider-
ation the studies and the RCTs on PAH patients published
in peer-reviewed journals or presented in recent major
meetings.
The grading system for the Level of Evidence based on
the number of RCTs may present some limitations that
need to be taken into account and possibly corrected.
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In fact, the level of evidence may change over time as
a result of additional studies performed. In addition,
the grading system does not address the sample sizes
of the RCTs as ‘‘small’’ RCTs are given the same weight
as larger ones. Moreover, the Level of Evidence for efﬁ-
cacy should not be confused with the Level of Clinical
Efﬁcacy, which depends on the net pharmacodynamic ef-
fects of the compound and on possible side effects and
shortcomings (e.g. complexity of the route of adminis-
tration). For example, a treatment strategy with better
results but with only one or no RCTs is rated respectively
B or C, as compared with a therapy with poorer results
and greater side effects assessed in more than one RCT
that can be rated as A. Also regulatory agencies may
grant approval to a given treatment on the basis of a sin-
gle RCT with an appropriate sample size and pre speci-
ﬁed adequate statistical requirements.
Accordingly, the Grade of Recommendation (Table 9)
was based on the Level of Clinical Efﬁcacy that is ex-
pected from the therapeutic procedure.
Finally, both components Grade of Recommendation
and Level of Evidence are provided in order to give a
complete proﬁle for each treatment (Table 10). No grade
of recommendation is given for drugs that are currently
available only for patients enrolled in RCTs. Country-spe-
ciﬁc regulatory approval status and labelling for each
compound is also provided (Table 11).
General measures
General measures include strategies devoted to limit the
deleterious impact of some circumstances and external
Table 8 Levels of evidence for efﬁcacy
Levels of Evidence
Level of Evidence A Data derived from multiple randomised clinical trials or meta-analyses
Level of Evidence B Data derived from a single randomised clinical trials or multiple trials with etherogeneous results
Level of Evidence C Consensus of opinion of the experts and/or small studies, retrospective studies, registries
Table 9 Grading using classes of recommendation
Class I Evidence and/or general agreement that a given diagnostic procedure/treatment is beneﬁcial, useful and effective;
Class II Conﬂicting evidence and/or a divergence of opinion about the usefulness/efﬁcacy of the treatment;
Class IIa Weight of evidence/opinion is in favour of usefulness/efﬁcacy;
Class IIb Usefulness/efﬁcacy is less well established by evidence/opinion;
Class III
a Evidence or general agreement that the treatment is not useful/effective and in some cases may be harmful.
a Use of Class III is discouraged by the ESC.
2256 ESC Guidelinesagents on patient with PAH. As for other clinical condi-
tions, the impact of these measures has not been tested
scientiﬁcally and the recommendations are based on the
experts’ opinion.
GradeofRecommendation = IIa;LevelofEvidence = C.
Physical activity – It is unclear whether physical
activity may have a negative impact on the evolution
of PAH. However, potentially hazardous symptoms like
Table 11 Country-speciﬁc regulatory approval and labelling for pulmonary arterial hypertension related therapeutic procedures
Treatment Country Labelling
Aetiology NYHA/WHO FC
Oral anticoagulants – – –
Diuretics – – –
Digoxin – – –
Oxygen – – –
Calcium channel blockers – – –
Epoprostenol Europe
a IPAH III–IV
USA, Canada IPAH and PAH-CTD III–IV
Treprostinil USA PAH II–III–IV
Iloprost (inhaled) European Union IPAH III
Australia IPAH, PAH-CTD and CTEPH III–IV
Iloprost (intravenous) New Zealand PAH III–IV
Beraprost Japan, Korea IPAH II–III–IV
Bosentan European Union PAH
b III
USA, Canada PAH III–IV
Sitaxsentan – – –
Ambrisentan – – –
Sildenaﬁl – – –
Balloon atrial septostomy – – –
Lung transplantation – – –
PAH-CTD: pulmonary arterial hypertension associated with connective tissue diseases; CTEPH: non-operable chronic thromboembolic pulmonary
hypertension; IPAH: idiopathic pulmonary arterial hypertension; PAH: pulmonary arterial hypertension.
a Epoprostenol in Europe has not been registered through the centralised procedure of the European Medecines Agency (EMEA) but it is approved
in different European countries on a local basis.
b Efﬁcacy has been shown in IPAH and PAH-CTD without signiﬁcant interstitial pulmonary disease.
Table 10 Grading of recommendations and level of evidence for efﬁcacy in idiopathic pulmonary arterial hypertension
Treatment Grade of recommendations Level of evidence
I IIa IIb
General measures X C
Oral anticoagulants
a XC
Diuretics X C
Digoxin XC
Oxygen
b XC
Calcium channel blockers
c XC
Epoprostenol X A
Treprostinil X B
Iloprost (inhalation) X B
Iloprost (intravenous) X C
Beraprost XB
Bosentan X
d A
Sitaxsentan
e B
Ambrisentan
e C
Sildenaﬁl X
d A
Combination therapy X C
Balloon atrial septostomy X C
Lung transplantation X C
a IIa for IPAH, IIb for other PAH conditions.
b If arterial oxygen saturation <90%.
c Only in patients responders to acute reactivity tests, I for IPAH, IIb for other PAH conditions.
d IIa B in NYHA class IV.
e These drugs are currently available only for patients enrolled in randomised controlled trials and no grade of recommendation is given.
ESC Guidelines 2257severe dyspnoea, syncope and chest pain should be
clearly avoided. Exercise should be limited to a symp-
tom-free level in order to maintain adequate skeletal
muscles conditioning. Physical activity after meals or in
extreme temperatures should be avoided. Appropriate
adjustments of daily activities may improve quality of
life and reduce the frequency of symptoms.
Travel/altitude – Hypoxia may aggravate vasocon-
striction in PAH patients and it is advisable to also avoid
mild degrees of hypobaric hypoxia that start at altitudes
between 1500 and 2000 m. Commercial airplanes are
pressurised to equivalent altitude between 1600 and
2500 m and supplemental oxygen in PAH patients should
be considered. Before planning to travel, information on
nearest PH clinics should be collected.
Prevention of infections – Patients with PAH are sus-
ceptible to develop pneumonia that is the cause of death
in 7% of cases. Pulmonary infections are poorly tolerated
and need to be promptly recognised and treated. Vaccine
strategies are recommended for inﬂuenza and pneumo-
coccus pneumonia. Any persistent fever in patients with
iv catheter for continuous administration of epoprostenol
should raise the suspicion of catheter infection.
Pregnancy, birth control and post-menopausal hor-
monal therapy
100 – Pregnancy and delivery in PAH pa-
tients are associated with an increased rate of
deterioration and death.
101,102 Even if successful preg-
nancies have been reported in IPAH patients,
103 an
appropriate method of birth control is highly recom-
mended in women with childbearing potential. There
is consensus among guidelines from the American Heart
Association, and the American College of Cardiology
which recommend that pregnancy be avoided or termi-
nated in women with cyanotic congenital heart disease,
PH, and Eisenmenger syndrome. The Expert consensus
document of the ESC on the management of cardiovas-
cular diseases during pregnancy outlines that severe pul-
monary vascular diseases has long been known to carry a
maternal mortality of 30–50%.
104 However, there is no
agreement among experts on the most appropriate birth
control method in these subjects. The safety of hor-
monal contraception is questioned for its inﬂuence on
prothrombotic changes. On the other hand, the current
availability of low-oestrogen dose products, and con-
comitant oral anticoagulant treatment may limit the risk
of these agents. In addition recent studies of large num-
bers of patients failed to reveal any relationship be-
tween intake of hormonal contraceptive agents and
PAH.
105 Some experts suggest the use of oestrogen-free
products or surgical sterilisation or barrier contracep-
tives. It is not clear if the use of hormonal therapy in
post-menopausal women with PAH is advisable or not.
Probably it can be suggested only in case of intolerable
menopausal symptoms and in conjunction with
anticoagulation.
Haemoglobin levels – Patients with PAH are highly
sensitive to reductions in haemoglobin levels. Any kind
of mild anaemia should be promptly treated. On the
other hand, patients with long-standing hypoxia, such
as those with right-to-left shunts, tend to develop eryth-
rocytosis with elevated levels of haematocrit. In these
circumstances, phlebotomies are indicated (see section
on Eisenmenger syndrome) if haematocrit is above 65%
in symptomatic patients (headache, poor concentration)
to reduce adverse effects of hyperviscosity.
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Concomitant medications – Care is needed to avoid
drugs that interfere with oral anticoagulants or increase
the risk of gastrointestinal bleeding. Even if non-steroid
anti-inﬂammatory drugs seem not to be associated to
PAH in a case-control study,
105 their use may further re-
duce glomerular ﬁltration rate in patients with low car-
diac output and pre-renal azotaemia. Anorexigens that
have been linked to the development of PAH are no longer
available on the market. The effects of the new genera-
tion serotonin-related anorexigens are unknown but no
reports of pulmonary-related side effects are available
up to now. The efﬁcacy of current treatments for chronic
‘‘biventricular’’ heart failure like ACE-inhibitors and
beta-blockers has not been conﬁrmed in patients with
PAH.
107 On the other hand, the empiric use of these
treatments, even at low doses, may result in severe side
effects like hypotension and right heart failure and
should be discouraged.
Psychological assistance – Patients with PAH have a
median age of about 40 years and exercise limitation
may interfere considerably with their previous life-style.
In addition, information on the severity of the disease
may be obtained from many non-professional sources.
Such sources may not be up-to date or may be confusing
or inappropriately explicit. For this reason, many PAH
patients are affected by a variable degree of anxiety
and/or depression that can have a profound impact on
their quality of life. The role of the PAH expert is impor-
tant in supporting patients with adequate information
(breaking bad news)
108 and in referring them to psychol-
ogists or psychiatrists when needed. Also support groups
for patients and families coordinated or not by psychol-
ogists or psychiatrists are useful in improving the
understanding and the acceptance of the disease
condition.
109
Elective surgery – Even if appropriate studies are
lacking it is expected that elective surgery has an in-
creased risk in patients with PAH. In addition, the risk
should increase with the severity of NYHA functional
class and in cases of thoracic and abdominal interven-
tions. It is not clear which type of anaesthesia is advis-
able but probably epidural is better tolerated than
general anaesthesia. The later should be performed by
experienced anaesthetists with the support of PH ex-
perts for deciding the most appropriate treatment in
case of complications. Patients on iv epoprostenol and
subcutaneous treprostinil treatment should have fewer
problems than subjects on oral or inhaled treatments.
The latter may suffer from temporary obstacles to the
drug administration like fasting, general anaesthesia
and assisted ventilation. In case a prolonged period of
withdrawal is foreseen (more than 12–24 h) it is advis-
able to provisionally shift to iv treatments and revert
to the original therapy subsequently. Anticoagulant
treatment should be interrupted for the shortest possi-
ble time and deep venous thrombosis prophylaxis should
be performed.
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Oral anticoagulant treatment
The rationale for the use of oral anticoagulant treat-
ment in patients with PAH is based on the presence
of traditional risk factors for venous thromboembo-
lism like heart failure and sedentary lifestyle as well
as on the demonstration of thrombophylic predisposi-
tion
41,42 and of thrombotic changes in the pulmonary
microcirculation
5,6 and in the elastic pulmonary
arteries.
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The evidence for favourable effects of oral anticoag-
ulant treatment in patients with IPAH or PAH associated
to anorexigens is based on retrospective analysis of sin-
gle centre studies.
79,111,112 The design of these studies
was not randomised and only IPAH and anorexigens-
related PAH patients were included in the studies.
The target INR in patients with IPAH varies somewhat
being 1.5–2.5 in most centres of North America and 2.0–
3.0 in European centres.
The evidence supporting anticoagulation in patients
with IPAH may be extrapolated to other patients with
PAH provided that the risk/beneﬁt ratio is carefully
considered.
For example, it is generally thought that the risk of
gastrointestinal bleeding may be higher in patients with
PAH associated with CTD. Patients with PAH associated
with congenital heart disease with intracardiac shunts
are at increased risk of hemoptysis but they may be also
at increased risk for paradoxical embolism in pulmonary
artery and cerebral vein thrombosis.
27 Patients with
porto-pulmonary hypertension may be at increased risk
for gastrointestinal bleeding due to the presence of var-
ices and low platelet counts. Patients with PAH receiv-
ing therapy with chronic iv epoprostenol are
anticoagulated in the absence of contraindications,
due in part to the additional risk of catheter-associated
thrombosis.
In recent RCTs, oral anticoagulants were administered
in 51–86% of subjects. Interestingly, the highest preva-
lence of oral anticoagulant treatment was seen in the tri-
als involving mainly IPAH patients in NYHA class III and IV,
while the lowest prevalence was observed in the trial
that included only patients with scleroderma.
113 It
should be emphasised that there is no evidence of any
difference in efﬁcacy of oral anticoagulant therapy
according to functional class or other measures of
severity.
Grade of Recommendation = IIa; Level of Evidence = C
for IPAH. Grade of Recommendation = IIb; Level of Evi-
dence = C for other PAH conditions.
Diuretics
Patients with decompensated right heart failure develop
ﬂuid retention that leads to increased central venous
pressure, abdominal organ congestion, peripheral oede-
ma and in advanced cases also ascites. Appropriate
diuretic treatment in case of right heart failure allows
clear symptomatic and clinical beneﬁts in patients with
PAH even if speciﬁc RCTs have not been performed. In
the recent RCTs on new targeted treatments, 49–70%
of patients were treated with diuretics. However, the
lack of trials with speciﬁc classes of diuretics in PAH
and the individual variability in responses leave the
choice of the type and the dose of drug to be used in indi-
vidual cases to the experience of the physician. Serum
electrolytes and indices of renal function should be fol-
lowed closely in patients receiving diuretic therapy.
Grade of Recommendation = I; Level of Evidence = C.
Oxygen
Most patients with PAH (except those with associated
congenital heart disease) present with only mild degrees
of arterial hypoxaemia at rest. The pathophysiological
mechanisms in this case include a low mixed venous oxy-
gen saturation caused by low cardiac output and only
minimally altered ventilation perfusion matching. In
some patients with profound hypoxaemia, a secondary
opening of a patent foramen ovale can be found. In pa-
tients with PAH associated with congenital cardiac de-
fects, hypoxaemia is related to reversal of left-to-right
shunting and is refractory to increased inspired oxygen.
No consistent data are currently available on the ef-
fects of long-term oxygen treatment in PAH. Although
improvement in PH with low-ﬂow supplemental oxygen
has been reported in some PAH patients, this has not
been conﬁrmed in controlled studies. However, it is gen-
erally considered important to maintain oxygen satura-
tion at greater than 90% at all times. More
controversial is the use of oxygen treatment in patients
with PAH associated with cardiac shunts. In fact, in a
controlled study on Eisenmenger syndrome patients, noc-
turnal oxygen therapy had no effect on haematological
variables, quality of life or survival.
114 In any case, the
effect of continuous oxygen administration in these cases
is unknown.
GradeofRecommendation = IIa;LevelofEvidence = C.
Digitalis and dobutamine
Since the depression of myocardial contractility seems to
be one of the primary events in the progression of right
heart failure, inotropic agents have been considered
for the treatment of this condition. Short-term iv admin-
istration of digoxin in IPAH produces a modest increase in
cardiac output and a signiﬁcant reduction in circulating
norepinephrine levels;
115 however, no data are available
on the effects of long-term treatment. Accordingly, the
use of digitalis in PAH patients with refractory right heart
failure is based primarily on the judgment of the physi-
cian rather than on scientiﬁc evidence of efﬁcacy. Digi-
talis may be used in the rare PAH patients with atrial
ﬁbrillation or atrial ﬂutter to slow ventricular rate. Di-
goxin was administered in 18–53% of patients enrolled
in recent RCTs in PAH. Patients with end stage PAH are
treated with iv dobutamine in most expert centres.
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This treatment often results in clinical improvement that
may persist for a variable period of time, like in ad-
vanced left heart failure.
Grade of Recommendation = IIb; Level of
Evidence = C.
ESC Guidelines 2259Calcium-channel blockers
The evidence for medial hypertrophy in the small pul-
monary arteries together with the reduction of PVR
obtained by vasodilator drugs lead Paul Wood many
years ago
34 to elaborate the ‘‘vasoconstrictive’’
hypothesis as the basis for understanding the patho-
genesis and the pathophysiology of IPAH. It is now
clear that only in a minority of patients with IPAH a
clinically signiﬁcant reduction of pulmonary artery
pressure associated with long-term clinical beneﬁts
can be achieved by the use of traditional vasodilators
such as CCBs.
Favourable clinical and prognostic effects of high
doses of CCBs in vasoreactive patients (see in the
‘‘Diagnosis and Assessment’’ section for deﬁnition of
positive acute vasoreactive response) with IPAH have
been shown in single centre, non-randomised, non-con-
trolled studies.
81,79,92,117 In these studies, the control
group consisted of non-vasoreactive patients who
may have a poorer prognosis ‘‘per se’’ as compared
to vasoreactive individuals.
92 However, there is no
clear evidence for this hypothesis and it would appear
unethical to withhold a therapy with high-dose CCB
from a patient with a consistent reduction of pulmon-
ary artery pressure by acute pharmacological testing
and to perform a placebo-controlled clinical trial in
these subjects.
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The CCBs that have been predominantly used in re-
ported studies are nifedipine and diltiazem and the
choice can be based upon the patient’s heart rate at
baseline (relative bradycardia favouring nifedipine,
and relative tachycardia favouring diltiazem). The doses
of these drugs that have shown efﬁcacy in IPAH are rel-
atively high i.e. up to 120–240 mg/day for nifedipine
and 240–720 mg/day for diltiazem.
79 It is advisable,
in vasoreactive patients, to start with reduced doses
(i.e. 30 mg of slow-release nifedipine bid or 60 mg of
diltiazem tid) to be increased cautiously and progres-
sively in the subsequent weeks to the maximal tolerated
regimen. Limiting factors for dose increase are usually
systemic hypotension and lower limb peripheral oede-
ma. In some cases the addition of digoxin and/or diuret-
ics can decrease the CCB side effects.
119 There are no
reports on efﬁcacy, tolerability and effective doses of
new generation CCBs such as amlodipine and ﬂodpine.
As reported above (‘‘Diagnosis and Assessment’’ sec-
tion) generally, only about 10–15% of IPAH will meet
the criteria for a positive acute vasoreactive response
and only about half of them will also be clinical and hae-
modynamic long-term responders to CCB treatment. It is
commonly accepted that only in these cases the contin-
uation of CCBs as single treatment is warranted.
The usefulness of acute vasoreactivity tests and long-
term treatment with CCBs in patients with PAH associ-
ated with CTD or congenital heart disease is less clear
as compared to IPAH.
81,86 However, experts suggest also
in these cases to test patients for acute vasoreactivity
and to treat cautiously the vasoreactive ones with oral
CCB, monitoring them closely to determine both the efﬁ-
cacy and safety of such therapy.
Favourable results of long-term administration of high
doses of calcium-channel antagonists have also been
shown in children with IPAH.
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Grade of Recommendation = I; Level of Evidence = C
for IPAH. Grade of Recommendation = IIb; Level of Evi-
dence = C for other PAH conditions.
Synthetic prostacyclin and prostacyclin analogues
Prostacyclin is produced predominantly by endothelial
cells and it induces potent vasodilatation of all vascular
beds studied. This compound is the most potent endoge-
nous inhibitor of platelet aggregation and it appears also
to have both cytoprotective and antiproliferative activi-
ties.
120 A dysregulation of the prostacyclin metabolic
pathways has been shown in patients with PAH as as-
sessed by a reduction of prostacyclin synthase expression
in the pulmonary arteries and of prostacyclin urinary
metabolites.
13 Even if it is not clear if the dysregulation
of the prostacyclin metabolic pathways has a causative
role or is merely a consequence of PH, it represents a
convincing rationale for the therapeutic use of prostacy-
clin in PAH patients. Initially, the clinical use of ‘‘prosta-
cyclin’’, i.e. epoprostenol, was based on its pulmonary
vasodilator properties that were shown in short term tri-
als, and this acute effect is currently utilised in testing
the vasoreactivity of pulmonary circulation. On the other
hand, even patients who do not manifest acute vasodila-
tor response to epoprostenol have shown clinical and
haemodynamic improvement with chronic treatment.
121
In fact, long-term iv administration of epoprostenol low-
ers PVR beyond the level achieved in the acute vasoreac-
tivity tests.
84 The hypotheses to explain these results are
based on the inhibitory effects of prostacyclin on vascu-
lar growth, remodelling and obliteration that can facili-
tate the partial restoration of altered functions of the
pulmonary microcirculation. However the precise mech-
anism of action of prostacyclin administration in PAH is
unknown and is likely to be multifactorial. It may include
relaxation of vascular smooth muscle cells (acute), inhi-
bition of platelet aggregation, normalisation of aggrega-
tion abnormalities, dispersion of platelets aggregates,
improvement of endothelial cells injury, inhibition of
vascular cells migration and proliferation facilitating re-
verse remodelling of pulmonary vascular changes,
improvement of pulmonary clearance of ET-1, direct
inotropic effect, enhanced peripheral O2 utilisation by
skeletal muscles and exercise haemodynamic
improvements.
13
The clinical use of prostacyclin in patients with PAH
has been extended by the synthesis of stable analogues
that possess different pharmacokinetic properties but
share qualitatively similar pharmacodynamic effects.
Originally, the experience on humans has been collected
with epoprostenol that is a synthetic salt of prostacyclin.
Epoprostenol – Epoprostenol is available as a stable,
freeze-dried preparation that needs to be dissolved to-
gether with an alkaline buffer (glycine), which allows a
solution to be infused intravenously. Epoprostenol has a
short half-life in the circulation (3–5 min), is rapidly con-
verted to stable breakdown products or metabolites and
2260 ESC Guidelinesis stable at room temperature for only 8 h; this explains
why it needs to be administered by continuous iv route by
means of infusion pumps (e.g. CADD
 pump) and perma-
nent tunnelised catheters (Hickman). The epoprostenol
is kept cool by using cold packs, which allows the infusion
to be changed daily. The use of subcutaneous catheters
with reservoirs and transcutaneous needles (used in
intermittent treatments) is discouraged.
The efﬁcacy of continuous iv administration of epo-
prostenol (synthetic prostacyclin) has been tested in 3
unblinded, controlled clinical trials in IPAH
121,122 and in
PAH associated with the scleroderma spectrum of dis-
eases,
113 and is summarised in Table 12. Epoprostenol
improves symptoms, exercise capacity and haemody-
namics in both clinical conditions, and is the only treat-
ment to be shown in RCTs to improve survival in IPAH.
Recently two large series of IPAH patients treated
with epoprostenol have been reported.
77,87 The data
showed that survival was about 65% at three years and
it was related to the severity at baseline, as well as to
the three-month response to therapy. The authors sug-
gested that lung transplantation should be considered
in a subset of patients who remain in NYHA functional
class III or IV or in those who cannot achieve a signiﬁcant
exercise and haemodynamic improvement after three
months of epoprostenol therapy, or both.
Long-term treatment with epoprostenol is initiated at
a dose ranging from 2 to 4 ng/kg/min and increased at a
rate limited by side effects (ﬂushing, headache, diar-
rhoea, leg pain). Target dose for the ﬁrst two to four
weeks is usually around 10–15 ng/kg/min and periodic
dose increases are then required to maximise efﬁcacy
and to maintain the results because of possible tolerance
to the drug. Optimal dose is variable between individual
patients ranging in the majority between 20 and 40 ng/
kg/min but the current strategy for increases is different
among centres. In two large recently published series of
patients treated with epoprostenol
77,87 mean dose was
21 ± 7 and 27 ± 8 ng/kg/min, respectively.
Adverse effects with chronic epoprostenol treatment
are common and include ﬂushing, jaw pain, diarrhoea,
headache, backache, foot and leg pain, abdominal
cramping, nausea, and rarely hypotension. The incidence
of side effects may relate to how aggressive the dose is
initially up titrated. Dose reduction is required only if
the intensity is moderate to severe. Recurrence of side
effects may be experienced after dose increases but usu-
ally they are mild and self-limiting over time without
dose changes. In some cases ascites has been reported
that may be related to an increased permeability of
the peritoneal membrane induced by epoprostenol. Ad-
verse events related to the delivery system are more
serious and are essentially linked to pump malfunction,
local site infection, catheter obstruction and sepsis. In
two large series
77,87 0.14 and 0.19 episodes of sepsis
per patients-year were reported and 8 deaths (2.8%)
out of a total of 340 subjects were directly related to
catheter infections. Localised infections can also occur
such as small exit site reactions, tunnel infections and
cellulitis. Rare events are pneumothorax and haemotho-
rax that occur during catheter insertion. Abrupt interrup-
tion of the epoprostenol infusion should be avoided, as
this may, in some patients, lead to a rebound worsening
of their PH with symptomatic deterioration and even
death. Management of patients on chronic epoprostenol
therapy requires a considerable infrastructure, including
experienced nurses and physicians.
Even if RCTs with epoprostenol have been performed
only in IPAH and PAH associated with scleroderma,
favourable results have also been shown in uncontrolled
experiences in other subsets such as paediatric IPAH
118
systemic lupus erythematosus
123 and other CTD,
124 PAH
associated with congenital heart defects with systemic
to pulmonary shunts either repaired or not,
124,125 in por-
to-pulmonary hypertension
124,126 in PAH associated to
Gaucher’s disease
127 and to HIV infection.
128 There is
no consensus among experienced physicians on the
effectiveness of epoprostenol treatment in patients with
Table 12 Randomised controlled trials with continuous intravenous epoprostenol in patients with pulmonary arterial hypertension
Trial IPAH
122 IPAH
121 PAH associated to scleroderma
113
Patients n 23 81 111
Duration (months) 2 3 3
NYHA functional class (%)
II 9 – 5
III 65 75 78
IV 26 25 17
Aetiology (%)
a
IPAH 100 100 –
CTD – – 100
CHD – – –
HIV – – –
Treatment effect
Six-min walk change (m) +45 +47 +94
Haemodynamics Improved Improved Improved
Clinical events Reduced Reduced (improved survival) No-change
CHD: congenital heart disease (congenital systemic to pulmonary shunts); CTD: connective tissue disease (PAH associated to scleroderma); IPAH:
idiopathic pulmonary aterial hypertension.
a Sum of % may not be 100% for rounding to the nearest unit, 0.5 is rounded to the upper unit.
ESC Guidelines 2261inoperable CTEPH even if some positive effects have
been shown.
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Epoprostenol in Europe has not been registered
through the centralised procedure of the European Union
(EMEA) but is approved in different European countries
on a local basis for IPAH in NYHA class III and IV. Epo-
prostenol is approved by the Food and Drug Administra-
tion (FDA) in the USA and Canada for IPAH and PAH
associated with CTD in NYHA class III and IV.
Grade of Recommendation = I; Level of Evidence = A
for IPAH and PAH associated with CTD.
Grade of Recommendation = IIa; Level of Evidence = C
for other PAH conditions.
Four RCTs have been performed with prostacyclin
analogues and are summarised in Table 13.
Treprostinil – Treprostinil is a tricyclic benzidene
analogue of epoprostenol, with sufﬁcient chemical sta-
bility to be administered at ambient temperature in a
physiological solution. These characteristics allow the
administration of the compound by iv as well as subcuta-
neous route. The subcutaneous administration of tre-
prostinil can be accomplished by micro-infusion pumps
(Mini-Med pump
) and small subcutaneous catheters sim-
ilar to those utilised for the administration of insulin in
diabetic patients. In this case, the problems linked to a
permanent central venous line, such as infections, are
avoided and the management of the system is much
simpler.
The effects of continuous subcutaneous administra-
tion of treprostinil in PAH were studied in the largest
worldwide RCT performed in this condition, and showed
improvements in exercise capacity, haemodynamics and
clinical events.
130 The greatest exercise improvement
was observed in patients who were more compromised
at baseline and in subjects who could tolerate upper
quartile dose (dose > 13.8 ng/kg/min). One earlier pilot
controlled study was performed with treprostinil in 26
PAH patients and showed trends in the improvement of
six-minute walk distance and in the reduction of PVR.
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Infusion site pain was the most common side effect of
treprostinil leading to discontinuation of the treatment
in 8% of cases on active drug and limiting dose increase
in an additional proportion of patients. Overall mortality
was 3% and no difference was detected between treat-
ment groups. Preliminary reports have shown the possi-
bility to transition patients from iv epoprostenol to
subcutaneous treprostinil.
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In 2002, the FDA approved the use of treprostinil in
NYHA class II, III and IV patients with PAH.
Grade of Recommendation = IIa; Level of Evidence = B
for PAH.
Sodium beraprost – Sodium beraprost is the ﬁrst
chemically stable and orally-active prostacyclin ana-
logue. It is absorbed rapidly in fasting conditions, peak
concentration is reached after 30 min and elimination
half-life is 35–40 min after single oral administration.
The orally-active prostacyclin analogue beraprost has
been evaluated in PAH patients in two RCTs in Europe
133
and in the United States
74 (Table 2). In the ﬁrst study the
drug was administered orally four times a day at the
highest tolerated dose (median dose 80 lg qid) and an in-
Table 13 Randomised controlled trials with new prostacyclin analogues in patients with pulmonary arterial hypertension
Trial Treprostinil
130 Beraprost – EU
133 Beraprost – USA
74 Iloprost
135
Patients n 469 130 116 203
Route Subcutaneous Oral Oral Inhaled
Duration (months) 3 3 12 3
NYHA functional class (%)
II 11 49 53 –
III 82 51 47 59
IV 7 – – 41
Aetiology (%)
ab
IPAH 58 48 74 54
CTD 19 7 10 17
CHD 24 21 16 –
CTEPH – – – 28
HIV – 7 – –
P-PH – 16 – –
Treatment effect
Peak VO2 (% predicted) N/A N/A Trend to increase N/A
Six-min walk change (m) 16
b 25 31
bc 36
Haemodynamics Improved No change No change Improved
d
Clinical events Reduced No-change Reduced
d Reduced
CHD; congenital heart disease (congenital systemic to pulmonary shunts); CTD: connective tissue disease; CTEPH: chronic thromboembolic
pulmonary hypertension; IPAH: idiopathic pulmonary arterial hypertension; N/A: not available; P-PH: porto-pulmonary hypertension.
a Sum of % may not be 100% for rounding to the nearest unit, 0.5 is rounded to the upper unit.
b Median change.
c Statistically signiﬁcant at 3 and 6 months.
d Only pulmonary vascular resistance improved in pre-inhalation period and a more consistent improvement of other parameters is observed in
post-inhalation period.
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jects after 3 months. In the second randomised trial that
lasted 12 months, improvement in exercise capacity was
observed at 3 and 6 months but not thereafter. No hae-
modynamic improvements were observed in the long-
term study and clinical events were reduced only at
the 6 month evaluation.
Beraprost sodium has been approved in Japan and
South-Korea for IPAH but its development appears to
have been stopped in the USA and in Europe.
Grade of Recommendation = IIb; Level of Evidence = B
for IPAH.
Inhaled iloprost – Iloprost is a chemically stable pros-
tacyclin analogue available for iv, oral and aerosol
administration. Inhaled therapy for PAH is an attractive
concept that has the theoretical advantage to be selec-
tive for the pulmonary circulation. In fact, since intra-
acinar pulmonary arteries are closely surrounded by
alveolar units, it is possible to vasodilate these vessels
by an alveolar deposition of vasodilators. It is critical
that aerosolised particles be small enough (diameter
3–5 lm) to ensure alveolar deposition.
After a single inhalation of iloprost a reduction of 10–
20% of mean pulmonary artery pressure was observed
and lasted for 45–60 min.
134 The short duration of action
requires frequent inhalations (from 6 to 12 times daily)
to obtain a persistent effect with long-term administra-
tion. With Jet nebulisers, the duration of each inhalation
takesabout15min; withalternative devicessuchasultra-
sound nebulisers the inhalation time can be reduced to
about 5 min.
Inhaled iloprost has been evaluated in one RCT in
which daily repetitive iloprost inhalations (6–9 times
2.5–5 lg/inhalation, median 30 lg daily) were compared
to placebo inhalation in patients with PAH and CTEPH
135
(Table 13). The study showed an increase in exercise
capacity and improvement in symptoms, PVR and clinical
events in IPAH patients only. Overall, inhaled iloprost
was well tolerated: cough occurred more frequently in
the iloprost group as well as ﬂushing and headache.
A long-term, uncontrolled study on 25 patients with
IPAH treated for at least one year with inhaled iloprost
100–150 lg daily has been also reported:
136 the data
showed a mean increase of 85 m of the six minutes walk,
a reduction of 7 mmHg in mean pulmonary artery pres-
sure and an increase in cardiac index of 0.6 l/min/m
2.
In a small study on 8 patients with PH and lung ﬁbrosis,
the acute administration of inhaled iloprost caused
marked pulmonary vasodilatation with maintenance of
gas exchange and systemic arterial pressure
137 showing
a possible usefulness in this particular subset of patients.
Inhaled iloprost treatment has been approved by the
EMEA in Europe for NYHA Class III IPAH and in Australia
and New Zealand for PAH and non-operable CTEPH class
III and IV.
Grade of Recommendation = IIa; Level of Evidence = B
for IPAH.
Intravenous iloprost – Continuous iv administration of
iloprost appears to be as effective as epoprostenol in a
small series of patients with PAH and CTEPH.
138,139 Ilo-
prost presents the advantage of being stable at room
temperature and does not need to be reconstituted and
refrigerated.
Continuous iv administration of iloprost has been ap-
proved in New Zealand for NYHA class III and IV PAH.
Grade of Recommendation = IIa; Level of Evidence = C
for PAH.
Endothelin-1 receptor antagonists
Endothelin-1 (ET-1), a peptide produced primarily by vas-
cular endothelial cells, is characterised as a powerful
vasoconstrictor and mitogen for smooth muscle.
14 ET-1
binds to two types of receptors, ETA and ETB:E T A-recep-
tors are found in smooth muscle cells whereas ETB-recep-
tors are localised on both endothelial cells and in smooth
muscle cells. Activation of ETA and ETB-receptors on
smooth muscle cells mediate the vasoconstrictive and
mitogenic effects of ET-1. Stimulation of endothelial
ETB-receptors promote ET-1 clearance and activation of
NO and prostacyclin release.
An activation of the ET-1 system has been demon-
strated in both plasma
140 and lung tissues of PAH pa-
tients.
141 Although it is not clear if the increases in
ET-1 plasma levels are a cause or a consequence of
PH,
140 studies on tissue ET system expression support a
prominent role of ET-1 in the pathogenesis of PAH.
14
The clear evidence of the activation of the ET system
in PAH provides a sound rationale for testing ET-1 antag-
onists in PAH patients. The most efﬁcient way to antag-
onise the ET-1 system is by the use of ET-1 receptor
antagonists that can block either ETA or both ETA and
ETB-receptors.
Currently three RCTs with endothelin-1 receptor
antagonists have been performed in PAH patients at
the time of writing (Table 14):
Bosentan – Bosentan is an oral active dual ETA and
ETB-receptor antagonist and is the ﬁrst molecule of this
class of drugs to be synthesised.
142 Bosentan has been
evaluated in PAH in two RCTs that have shown improve-
ment in exercise capacity, functional class, haemody-
namics, echocardiographic and Doppler variables, and
time to clinical worsening.
58,143,144 In the larger
BREATHE-1 study, patients were randomised 1:1:1 to re-
ceive placebo or 62.5 mg of bosentan twice daily for 4
weeks followed by either bosentan 125 mg bid or 250
mg bid for a minimum of 12 weeks. Although both bosen-
tan dosages induced a signiﬁcant treatment effect, the
placebo-corrected improvement tended to be more pro-
nounced for the 250 mg bid than for the 125 mg bid dos-
age (+54 m and +35 m of 6MWT treatment effect,
respectively). However, no formal dose response for efﬁ-
cacy could be ascertained. Although a similar treatment
effect was achieved in patients with IPAH and in those
with PAH associated with scleroderma, bosentan im-
proved the walking distance from baseline in IPAH pa-
tients (+46 m in the bosentan group versus  5 m in the
placebo group) whereas it prevented walk distance dete-
rioration in the scleroderma patients (+3 m in the bosen-
tan group versus  40 m in the placebo group). Increases
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jects, and were found to be dose-dependent and revers-
ible after dose reduction or discontinuation. In fact,
abnormal hepatic function was more frequent and severe
in the 250 mg dose group and a decrease in transaminase
concentrations was observed in all cases in which the
bosentan dose was reduced. Based on these results, the
recommended target therapeutic dose of bosentan was
conﬁrmed as 125 mg twice daily. The most likely mecha-
nism for the liver enzyme changes with Bosentan treat-
ment is a dose-dependent competition by bosentan and
its metabolites with the biliary excretion of bile salts,
resulting in a retention of bile salts that can be cytotoxic
to hepatocytes.
145
Twenty-nine patients received bosentan in an exten-
sion study: patients assessed at month 6 maintained
the improvement in walk distance, and long-term treat-
ment with bosentan for >1 year was associated with an
improvement in haemodynamic parameters and NYHA
functional class.
146
Oral bosentan has also recently been proposed as a
transition therapy in patients displaying severe and/or
unbearable side effects of prostanoid therapy including
sepsis with iv epoprostenol.
147
An open-label, uncontrolled single and multiple-dose
study has been performed in children 4–17 years of age
with PAH (BREATHE-3) to assess pharmacokinetics, toler-
ability and safety of oral bosentan. In this preliminary
study a signiﬁcant improvement in haemodynamics was
observed after 12 weeks of treatment in the 18 enrolled
children either with bosentan alone or in combination
with epoprostenol.
148
Due to the potential increase in liver enzymes, the
FDA requires that liver function tests be performed at
least monthly in patients receiving bosentan. In addition
the EMEA recommended to monitor monthly liver func-
tion tests, and currently these data are collected in an
internet-based program (TRAX). Also the haemoglobin/
haematocrit should be checked regularly because bosen-
tan use may also be associated with the development of
anaemia, which seems typically to be mild. Fluid reten-
tion and lower limb oedema have been also reported in
patients treated with Bosentan. Careful attention must
be paid to the use of adequate contraception in women
of childbearing age due to the potential teratogenic ef-
fects of bosentan. In addition bosentan may decrease
the efﬁcacy of hormonal contraceptive techniques, and
for this reason they should not be used alone. There is
concern that the endothelin antagonists as a class may
be capable of causing testicular atrophy and male infer-
tility. Younger males who may consider conceiving
should be counselled regarding this possibility prior to
taking these drugs.
Bosentan has been approved for the treatment of
NYHA class III and IV PAH patients in the USA and Canada.
In Europe it has been approved by the EMEA for the treat-
ment of NYHA class III patients specifying that efﬁcacy
has been demonstrated only in IPAH patients and PAH
associated with scleroderma without signiﬁcant lung
ﬁbrosis.
Grade of Recommendation = I; Level of Evidence = A
for NYHA class III IPAH and PAH associated with sclero-
derma without signiﬁcant lung ﬁbrosis.
Grade of Recommendation = IIa; Level of Evidence =B
for NYHA class IV IPAH and PAH associated with sclero-
derma without signiﬁcant lung ﬁbrosis.
Sitaxsentan – Sitaxsentan, a selective orally-active
ETA-receptor antagonist has been assessed in PAH pa-
tients in one RCT on 178 patients with NYHA class II, III
Table 14 Randomised controlled trials with endothelin-1 receptor antagonists in patients with pulmonary arterial hypertension
Trial Bosentan pilot
143 Bosentan pivotal
144 Sitaxsentan
75
Patients n 32 213 178
Route Oral Oral Oral
Duration (months) 3 4 3
Primary end points 6-min walk 6-min walk Peak-VO2
NYHA functional class (%)
II – – 33
III 100 91 66
IV – 9 1
Aetiology (%)
a
IPAH 85 70 53
CTD 15 30 24
CHD – – 24
HIV – – –
Treatment effect
Peak VO2 (% predicted) N/A N/A +3%
b
Six-min walk change (m) +76 +44 +34
Hemodynamics Improved N/A Improved
Clinical events Reduced Reduced Reduced
c
CHD: congenital heart disease (congenital systemic to pulmonary shunts); CTD: connective tissue disease; IPAH: idiopathic pulmonary arterial
hypertension; N/A: not available.
a Sum of % may not be 100% for rounding to the nearest unit, 0.5 is rounded to the upper unit.
b Only for 300 mg dose.
c Only for 100 mg dose.
2264 ESC Guidelinesand IV PAH.
75 Aetiology included IPAH and PAH associ-
ated with CTD or congenital heart diseases. Patients
were randomised 1:1:1 to placebo, sitaxsentan 100 mg,
or sitaxsentan 300 mg given orally once daily for 12
weeks. The study demonstrated improvements in exer-
cise capacity, haemodynamics and clinical events.
75 Inci-
dence of abnormal liver function tests, which reversed in
all cases, was 0% for 100 mg, and 9.5% for 300 mg. An
additional pilot study with this compound in 20 PAH pa-
tients has shown similar results.
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Sitaxsentan may increase the international norma-
lised ratio (INR) or prothrombin time (PT), due to the
inhibition of CYP2C9 P450 enzyme, the principal hepatic
enzyme involved in the metabolism of warfarin. This
interaction can be managed by reducing the warfarin
dose to achieve the desired INR.
A second RCT is currently ongoing with sitaxsentan to
further explore both efﬁcacy and side effects proﬁle and
to achieve approval from regulatory agencies. No grade
of recommendation is given for sitaxsentan because it
is currently available only for patients enrolled in RCTs.
Grade of Recommendation = currently not given; Le-
vel of Evidence = B.
Ambrisentan – Ambrisentan, a selective orally-active
ETA-receptor antagonist has thus far been evaluated in a
pilot blinded dose-comparison study in 64 PAH patients.
Preliminary results show improvements in exercise
capacity and haemodynamics that appear similar to the
results observed with the other ERAs.
150 Two RCTs are
currently ongoing with ambrisentan to further explore
both efﬁcacy and side effects proﬁle and to achieve ap-
proval from regulatory agencies. No grade of recommen-
dation is given for ambrisentan because it is currently
available only for patients enrolled in RCTs.
Grade of Recommendation = currently not given; Le-
vel of Evidence = C
Type 5 phosphodiesterase inhibitors
Sildenaﬁl – Sildenaﬁl is an orally-active, potent and
selective inhibitor of cGMP-phosphodiesterase (PDE) type
5, that exerts its pharmacological effect by increasing the
intracellular concentration of cGMP.
151 The increase of
this nucleotide induces relaxation and antiproliferative
effects on vascular smooth muscle cells.
152 PDE-5 is
selectively abundant in the pulmonary circulation
153,154
and PDE-5 gene expression and activity are increased in
chronic PH.
155,156 This suggests that sildenaﬁl may have
a prefential effect on the lung vasculature.
A number of uncontrolled studies have reported
favourable effects of the orally-active type 5 phospho-
diesterase inhibitor sildenaﬁl in PAH,
157–159 CTEPH
160
and PH associated with lung ﬁbrosis.
161 The drug at a
dose ranging from 25 to 75 mg tid appears to improve
both cardiopulmonary haemodynamics and exercise
capacity. These studies report relatively few minor
side effects (e.g., headache, nasal congestion, and vi-
sual disturbances). A RCT with a cross-over design has
been recently published: sildenaﬁl 25–100 mg tid
administered in 22 NYHA II and III PAH patients improved
symptoms after 6 weeks, the exercise capacity as as-
sessed by the Naughton protocol on the treadmill (from
475 ± 168 s of exercise time at the end of placebo phase
to 686 ± 224 s at the end of sildenaﬁl phase) and the hae-
modynamics.
15 The results of a pivotal RCT of 278 NYHA II
and III PAH patients were recently presented at the Amer-
ican College of Chest Physicians meeting at the end of
October 2004. The data show that mean placebo-
corrected treatment effects on 6MWT were around
45 m for 20, 40, and 80 mg sildenaﬁl 3 times daily. All
sildenaﬁl doses reduced mPAP at week 12 by about 3 to
5 mmHg. At the time of writing sildenaﬁl treatment has
not yet been approved by any regulatory agency for treat-
ment of PAH.
162 Currently, treatment with sildenaﬁl
should be considered in patients with PAH, who have
failed or are not candidates for other approved therapies.
Grade of Recommendation = I; Level of Evidence = A.
Combination therapy
Combination therapy is an attractive option to address
the multiple pathophysiological mechanisms that are
present in PAH. Combination therapy can be pursued by
the simultaneous initiation of two (or more) treatments
or by the addition of a second (or third) treatment to a
previous therapy that may be considered insufﬁcient.
Which of these two strategies is the best choice is cur-
rently unknown.
The efﬁcacy and safety of the concurrent initiation of
bosentan and epoprostenol were investigated in 33 NYHA
class III and IV PAH randomised either to an epoprost-
enol+placebo group or an epoprostenol+bosentan group
(BREATHE-2). Improved haemodynamics, exercise capac-
ity and functional class were observed in both groups.
Data shows that there was a trend for a greater (though
non-signiﬁcant) improvement in all haemodynamic
parameters in the eportostenol+bosentan group.
163 How-
ever, an increase of adverse events was observed in the
combination group as compared to epoprostenol alone.
Further RCT is ongoing or planned that will explore
the effects of the addition of sildenaﬁl to patients al-
ready on epoprostenol.
In patients with PAH who were deteriorating despite
chronic treatment with non-parenteral prostanoids,
addition of bosentan
164 or sildenaﬁl
165 to the ongoing
treatment resulted in favourable improvements in pul-
monary haemodynamics and exercise capacity in uncon-
trolled studies.
GradeofRecommendation = IIb;LevelofEvidence = C.
Interventional procedures
Balloon atrial septostomy
Several experimental
166 and clinical
167 observations have
suggested that an inter-atrial defect might be of beneﬁt
in the setting of severe PH. In fact the presence of an at-
rial septal defect would allow right-to-left shunting to in-
crease systemic output that, in spite of the fall in
systemic arterial oxygen saturation will produce an in-
crease in systemic oxygen transport. Furthermore, the
shunt at the atrial level would allow decompression of
ESC Guidelines 2265the right atrium and right ventricle, alleviating signs and
symptoms of right heart failure.
The role of balloon atrial septostomy in the treatment
of PAH patients is uncertain because its efﬁcacy has been
reported only in small series and case reports, totalling
approximately 120 published cases.
168,169 In most circum-
stances, this intervention has been performed in severely
ill patients as a palliative bridge to lung transplantation,
which may explain a procedure mortality rate ranging
from 5% to 15%. In addition to symptomatic and haemody-
namic improvement, an increase in survival as compared
with historical control groups has also been shown.
76 At
present, balloon atrial septostomy is indicated for ad-
vanced NYHA class III and class IV patients with recurrent
syncope and/or right heart failure despite all available
medical treatments; septostomy is used either as a palli-
ative bridge to lung transplantation or as the sole treat-
ment modality when other options are not available.
169
Balloon atrial septostomy should be performed only in
experienced centres to reduce the procedural risks.
GradeofRecommendation = IIa;LevelofEvidence = C.
Lung transplantation
Lung and heart-lung transplantation in PAH have been as-
sessed only in prospective uncontrolled series, since for-
mal RCTs are considered unethical in the absence of
alternative treatment options.
169
The 3 and 5 year survival after lung and heart-lung
transplantation is approximately 55% and 45%,
respectively.
170
Both single and bilateral lung transplantation have
been performed for IPAH and these operations have been
combined with repair of cardiac defects for the Eisenm-
enger syndrome. Recipient survival rates have been sim-
ilar after single and bilateral transplantation for PAH,
and if technically feasible, either of these operations is
an acceptable choice for most cases of PAH. However,
many transplant centres currently prefer to perform
bilateral lung transplantation in part because there are
generally less postoperative complications. In patients
with Eisenmenger syndrome and in those with end-stage
heart failure, the option of heart-lung transplantation
should be carefully considered. For some complex de-
fects, and in cases of ventricular septal defects, a sur-
vival advantage of heart-lung transplantation has been
shown.
Lung and heart-lung transplantation are indicated in
PAH patients with advanced NYHA class III and class IV
symptoms that are refractory to available medical treat-
ments. The unpredictability of the period on the waiting
list and donor organ shortage complicate the decision-
making regarding the appropriate timing of listing for
transplantation.
Grade of Recommendation = I; Level of Evidence = C.
Treatment algorithm
A treatment algorithm based on the Grade of Recommen-
dation and The Level of Evidence derived by clinical tri-
als is reported in Fig. 3.
The algorithm is restricted to patients in NYHA func-
tional class III or IV because they represent the predom-
inant population included in RCTs.
For NYHA class I or II patients very few data are avail-
able and the most appropriate strategy has still to be
determined and possibly validated by speciﬁc studies.
Currently, NYHA class I and II patients should be treated
with background therapy and, if vasoreactive, with CCBs.
In cases with multiple favourable prognostic indicators
(see the section on Assessment of Severity) a watchful-
waiting strategy or inclusion in RCTs is recommended.
The different treatments have been evaluated mainly
in IPAH, and in PAH associated with scleroderma or to
anorexigen use. Extrapolation of these recommenda-
tions to the other PAH subgroups should be done with
caution (See the section on Speciﬁc Conditions).
The suggested initial approach, after the diagnosis of
PAH is made, is the adoption of the general measures and
initiation of the background therapy that includes oral
anticoagulant drugs (if no contraindications exist),
diuretics in case of ﬂuid retention, supplemental oxygen
in case of hypoxaemia and digoxin in case of refractory
right heart failure and/or supraventricular arrhythmias.
Due to the complexity of the additional evaluation
and the treatment options available, it is strongly rec-
ommended that patients with PAH are referred to a
specialised centre.
Acute vasoreactivity testing should be performed in
all patients with PAH, although patients with IPAH and
PAH associated to anorexigens use are the most likely
to exhibit an acute positive response and to beneﬁt from
high-dose CCB therapy.
Vasoreactive patients, as deﬁned above, should be
treated with optimally tolerated doses of CCB; mainte-
nance of the response (deﬁned as NYHA functional class
I or II with near normal haemodynamics) should be con-
ﬁrmed after three to six months of treatment.
Non-responders to acute vasoreactivity testing who
are in NYHA functional class I and II should continue with
the background therapy under close clinical follow-up.
Non-responders to acute vasoreactivity testing, or
responders who remain in NYHA functional class III should
be considered candidates for treatment with either an
endothelin receptor antagonist (ERA) or a prostanoid. At
present, the only commercially available and approved
ERA is the orally-active dual receptor antagonist bosen-
tan. Among prostanoids, treprostinil is administered sub-
cutaneously and has been approved in the USA; Iloprost,
administered by aerosol, has been approved in Europe
and Australia, while beraprost is approved in Japan and
South-Korea. Continuous iv administration of epoprost-
enol may also be used in NYHA class III patients who are
refractory to ERAs or other prostanoids. Some authors
still use ﬁrst-line epoprostenol in NYHA class III patients,
due to its demonstrated survival beneﬁts.
The choice of the drug is dependent on a variety of
factors, including the approval status, route of adminis-
tration, side effect proﬁle, patient’s preferences and
physician’s experience.
The orally-active type 5 phosphodiesterase inhibitor
sildenaﬁl is currently not approved for the treatment of
2266 ESC GuidelinesPAH by any regulatory agency, and its use should be con-
sidered in subjects who have failed or are not candidates
for other approved therapy.
The role of this drug will be better deﬁned after the
evaluation of the pivotal RCT data byregulatory agencies.
Continuous iv epoprostenol, approved in the US and
Europe, may be considered as ﬁrst line therapy for IPAH
patients in NYHA functional class IV because of the dem-
onstrated survival beneﬁt in this subset.
Although both bosentan and treprostinil are approved
in class IV patients, only a small number of class IV pa-
tients were included in the clinical trials of these agents.
Accordingly, most experts consider these treatments
as a second line for severely ill patients. Although no
RCTs have been performed with the iv delivery of
iloprost, this prostacyclin analogue has been approved
in New Zealand.
Combination therapy (e.g. ERAs + prostanoids) may be
considered for patients who fail to improve or deterio-
rate with ﬁrst-line treatment, even though data on this
speciﬁc strategy are limited and largely uncontrolled at
this point. Appropriate protocols for timing and dosing
to limit possible side effects of the combination have still
to be implemented.
Balloon atrial septostomy and/or lung transplantation
are indicated for refractory PAH or where medical treat-
ments are unavailable. These procedures should be per-
formed only in experienced centres.
Endothelin R Antagonists 
Bosentan (I A)
or 
Prostanoid Analogues
Iloprost inh (IIa B), Treprostinil (IIa B),
Beraprost (IIb B),
or
Continuous IV prostacyclin
Epoprostenol (I A)
or
PDE5 inhibitors (7)
Sildenafil (I A)
Oral CCB (I C)
Continue 
CCB
Sustained
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Yes No
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Epoprostenol (I A)
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Treprostinil (IIa B)
Iloprost iv (IIa C)
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Combination 
Therapy ? (IIb C)
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Background Therapy and General Measures
Oral anticoagulants (IIa C), Diuretics (I C), O2(IIa C), Digoxin (IIb C)
NYHA Class IV (8) NYHA Class III (6)
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Fig. 3 Evidence-based treatment algorithm. (1) The algorithm is restricted to patients in NYHA functional class III or IV because they represent the
largest population included in controlled clinical trials. For NYHA class I or II very few data are available. In addition the different treatments have been
evaluated mainly in sporadic idiopathic pulmonary arterial hypertension patients (IPAH), and in PAH associated with scleroderma or to anorexigen use.
Extrapolation of these recommendations to the other PAH subgroups should be done with caution. (2) Due to the complexity of the acute vasoreactivity
tests, and of the treatment options available, it is strongly recommended that consideration be given to referral of patients with PAH to a specialised
centre. (3) Acute vasoreactivity test should be performed in all patients with PAH even if the greater incidence of positive response is achieved in
patients with IPAH and PAH associated to anorexigen use. (4) A positive acute response to vasodilators is deﬁned as a fall in mean pulmonary artery
pressure of at least 10 mmHg to less than or equal to 40 mmHg, with an increase or unchanged cardiac output during acute challenge with inhaled NO, iv
epoprostenol, or iv adenosine. (5) Sustained response to calcium channel blockers (CCB) is deﬁned as patients being in NYHA functional class I or II with
near normal hemodynamics after several months of treatment. (6) In patients in NYHA functional class III, ﬁrst line therapy may include oral endothelin
receptor antagonists, chronic iv epoprostenol, or prostanoid analogues. (7) At the time of writing sildenaﬁl is not approved for PAH by any regulatory
agency. (8) Most experts consider that NYHA functional class IV patients in unstable condition should be treated with iv epoprostenol (survival
improvement, worldwide experience and rapidity of action). A, B, C grading according to Tables 4 and 5; CCB: calcium channel blockers; inh: inhaled; iv:
continuous intravenous; PDE: phophodiesterase; R: receptors.
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Paediatric pulmonary arterial hypertension
Incidence – The prevalence of congenital heart disease is
higher amongst children than adults and great care is
needed to recognise this important cause of PAH. In con-
trast, the prevalence of PAH related to CTD, portal
hypertension, HIV infection and drugs/toxins is lower
amongst children than adults. Although persistent PH of
the newborn (PPHN) is also classiﬁed under PAH, its nat-
ural history and treatment are sufﬁciently different from
those in other forms of PAH to justify its exclusion from
further discussion here. PPHN is usually transient,
171,172
with infants either recovering completely without requir-
ing chronic medical therapy or dying during the neonatal
period despite maximal cardiopulmonary therapeutic
interventions.
173
Pathogenesis – No clear differences have been iden-
tiﬁed among the mechanisms involved in the develop-
ment of PAH in children and in adults. However, PPHN
may entail some speciﬁc pathophysiological mechanisms
due to the persistence of the foetal pulmonary vascular
characteristics and of the patent foramen ovale.
174 In
addition, prevalence of acute vasoreactivity is higher
in children with IPAH suggesting that vasoconstriction
may prevail on ﬁxed obstructive vascular changes in this
subset.
79,118
Clinical picture and investigations – Clinical, diagnos-
tic and prognostic data on PAH have been collected pre-
dominantly in the adult population and often
extrapolation of this information on the paediatric popu-
lation is required.
On the basis of the NIH registry, it was raised that
there is a higher mortality in children than adult patients
if untreated. However, those data were collected on
small numbers of paediatric cases, and preceded the
availability of many of the current medical therapies.
Theoretically, it might also be expected that the re-
sponse to treatment would be better in children because
the vasculature is still remodelling as the child grows.
The new medical treatments do indeed appear to
achieve greater success in children than in adults with
PAH, but the course of the disease is less predictable.
175
It remains unclear as to why one child should behave dif-
ferently from another when troubled by the same degree
of PAH.
Despite the fact that only single centre reports are
available on the diagnostic strategy, children with severe
PH undergo a similar diagnostic evaluation as has been
described in adults (see above).
176 Studies include arte-
rial blood gas and oxygen saturation measurements, a
chest radiograph, pulmonary function and exercise test-
ing, echocardiogram, ventilation-perfusion scan, chest
CT, abdominal ultrasound scan, serological studies for
CTD, studies of hypercoagulability, and HIV testing; diag-
nosis needs to be conﬁrmed by the right heart catheter
study.
As in adults with severe PAH, testing of pulmonary
vasoreactivity during RHC includes assessment of the
acute response to a short-acting vasodilator, such as in-
haled NO, iv epoprostenol or iv adenosine, to determine
if there is a role for chronic therapy with an oral CCB.
The prevalence of acute vasoreactivity is higher in chil-
dren than adults and this permits more children than
adults to be effectively treated with CCB.
79,118
Treatment – The therapeutic algorithm for children
who have PAH is similar to that used in adults, however,
a few speciﬁc issues need to be addressed. For example,
in children who are responsive to a speciﬁc treatment
strategy, the response is often far better than that seen
in adult patients. Conversely, if they fail to respond to
these therapeutic modalities, their survival is often even
shorter than that of adult patients with severe disease.
Since the children with PAH often have a more reac-
tive pulmonary vascular bed than the adults, any respira-
tory tract infection that results in ventilation/perfusion
mismatching from alveolar hypoxia can result in a cata-
strophic event if not aggressively treated. We recom-
mend that children with pneumonia be hospitalised for
the initiation of antibiotic therapy, with antipyretics
administered for temperature elevations greater than
101 F (38 C) to minimise the consequences of increased
metabolic demands.
Whether or not chronic anticoagulation is efﬁcacious
in children with PAH, as well as safe with a low risk/ben-
eﬁt proﬁle remains to be determined. However, the cur-
rent approach of experts is to anticoagulate children
with right heart failure.
The safety and efﬁcacy of CCBs is based on a patient’s
response to acute vasodilator testing, and the efﬁcacy of
this treatment in children is similar to that in adults. The
optimal dosage regime used is usually relatively high as in
adults (see above) and children tolerate and appear to
need, a higher dose per kilogram than adults.
Clinical indications for chronic iv epoprostenol ther-
apy in children are similar to adults. The optimal dose
of epoprostenol remains unclear in both children and
adults. In children, the starting dose is 2 ng/kg/min, as
in adults, and the dose is increased as necessary. The
dose usually has to be increased quite rapidly during
the ﬁrst months after initiating treatment. Although a
mean dose at one year for an adult PAH patient is approx-
imately 20–40 ng/kg/min, the mean dose at one year in
children, particularly young children, is closer to 50–80
ng/kg/min and the ‘‘optimal’’ dose varies considerably
in different patients.
Oral beraprost, inhaled iloprost and subcutaneously
infused treprostinil have all been used with to treat chil-
dren with PAH, with varying degrees of success. In prac-
tice, it can be difﬁcult to dose young children effectively
with inhaled iloprost, even when they are co-operative,
and subcutaneous treprostinil can be too painful. Experi-
ence suggests that, as with iv epoprostenol, children
need to be given a higher dose per kilogram than adults.
An open-label, uncontrolled single and multiple-dose
study has been performed in children 4–17 years of age
with PAH (BREATHE-3) to assess pharmacokinetics, toler-
ability and safety of oral bosentan. In this preliminary
study a signiﬁcant improvement of haemodynamics was
observed after 12 weeks of Bosentan treatment in the
2268 ESC Guidelines18 enrolled children either alone or in combination with
iv epoprostenol.
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The use of type 5 phosphodiesterase inhibitors, such
as sildenaﬁl, has been described in children, but, data
are limited to small case series.
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Pulmonary arterial hypertension associated to
Eisenmenger syndrome
Incidence – See discussion on Eisenmenger syndrome in
the Classiﬁcation section on congenital systematic-to-
pulmonary shunts above.
Pathogenesis – Eisenmenger syndrome is deﬁned as a
congenital heart defect that initially causes large left-to-
right shunt that induces severe pulmonary vascular dis-
ease and PAH, with resultant reversal of the direction
of shunting.
179 With initial left-to-right shunting, the
exposure of the pulmonary vasculature to increased
blood ﬂow as well as increased pressure may result in
pulmonary vascular obstructive disease and, as the PVR
approaches or exceeds systemic resistance, the shunt is
reversed.
Clinical picture and investigations – Most patients
will have impaired exercise tolerance and exertional
dyspnoea, but these symptoms may be well compensated
for years. Hemoptysis may occur, as a result of rupture of
dilated bronchial arteries. Since patients with reduced
arterial oxygen saturation have abnormal haemostasis,
they are at risk for both bleeding and thrombosis. Cere-
brovascular accidents may occur as a result of paradoxi-
cal embolisation, venous thrombosis of cerebral vessels,
or intracranial haemorrhage. In addition, patients with
this condition are at risk for brain abscess. Patients with
Eisenmenger syndrome may have syncope owing to inad-
equate cardiac output or, less commonly, an arrhythmia.
Symptoms of heart failure, which are uncommon until
the disease is far advanced, portend a poor prognosis.
Survival of patients with Eisenmenger syndrome is better
than that of subjects with IPAH or APAH with comparable
functional class. In a series of 100 patients listed for
transplantation, actuarial survival of patients who did
not receive transplants was 97% at 1 year, 89% at 2 years,
and 77% at 3 years for patients with Eisenmenger syn-
drome and 77%, 69%, and 35%, respectively, for patients
with IPAH.
180
Treatment – The recommendation given for the
treatment of Eisenmenger syndrome patients are mainly
based on the clinical experience of experts and not on
speciﬁc RCTs.
106,181 Phlebotomy with isovolumic
replacement should be performed in patients with mod-
erate or severe symptoms of hyperviscosity (e.g. head-
ache and poor concentration) that usually are present
when haematocrit is >65%; it should not be performed
in asymptomatic or mildly symptomatic patients (regard-
less of the haematocrit). The symptoms are usually re-
lieved by removal of one unit of blood, always with an
equal volume replacement of dextrose or saline.
106 Phle-
botomies should be performed no more than 2–3 times
per year to avoid depletion of the iron stores and the pro-
duction of iron-deplete red cells that increase blood vis-
cosity. Diuretics can be used in case of signs of right
heart failure.
The use of supplemental oxygen therapy is controver-
sial
182andshouldbeusedonlyincasesinwhichitproduces
a consistent increase in arterial oxygen saturation and/or
improved clinical well being (pulmonary restrictive com-
ponent).Insomecentres,Eisenmengersyndromepatients
are anticoagulated similarly to other subjects with PAH in
the absence of contraindication. Other authors suggest to
avoid this treatment that can exacerbate the haemor-
rhagic diathesis.
183
Unfortunately, few RCTs evaluating the effects of
the new medical regimens in PAH have included pa-
tients with the Eisenmenger syndrome.
127,130,133 One
reason for this is that the natural history of the un-
treated Eisenmenger syndrome, despite being signiﬁ-
cantly worse than that of the normal population, is in
most cases a very slowly progressive disease, making
RCTs difﬁcult. Although the natural history of IPAH
and PAH associated with congenital heart disease is
very different, the similarity in their histopathology sug-
gests that a common approach to treatment may be
appropriate and effective. However, the efﬁcacy of
the new treatments should be formally tested to clarify
the beneﬁt-to-risk ratio.
The use of iv epoprostenol has been shown to exert
favourable effects on haemodynamics and exercise
capacity
125 and the effects of subcutaneous treprostinil
in Eisenmenger patients was not different from that on
IPAH.
132 A RCT to assess the effects of bosentan on 65
Eisenmenger patients is currently ongoing (BREATHE-5).
Lung transplantation with repair of the cardiac defect
or combined heart-lung transplantation is an option for
patients with Eisenmenger syndrome who have markers
of a poor prognosis (syncope, refractory right-sided heart
failure, NYHA functional class III or IV, or severe hypox-
emia). Because of the somewhat limited success of trans-
plantation and the reasonably good survival among
patients treated medically, careful selection of patients
for transplantation is imperative.
Porto-pulmonary hypertension
Incidence – PAH is a well-recognised complication of
chronic liver diseases.
184,185,186 Portal hypertension
rather than the hepatic disorder itself seems to be the
main determining risk factor for developing PH, leading
to the concept of porto-pulmonary hypertension.
185 Ini-
tially described by Mantz and Craige in 1951, porto-pul-
monary hypertension is sufﬁciently infrequent so that it
was debated for a long time whether this association
was coincidental or causally related. Several lines of evi-
dence suggest that the existence of portal hypertension
and the development of PAH is non-coincidental.
185,187
Indeed, the incidence of PAH in patients with portal
hypertension is much higher than the estimated inci-
dence of IPAH in the general population. A large retro-
spective autopsy study showed that PAH occurred in
0.13% of overall unselected autopsied patients, versus
0.73% of patients with cirrhosis and portal hypertension.
ESC Guidelines 2269Two prospective haemodynamic studies showed that 2%
of patients with cirrhosis and portal hypertension had sig-
niﬁcant PAH. Two recent studies carried out in patients
undergoing liver transplantation found a prevalence of
pulmonary hypertension of 4% and 3.5%, respectively. Fi-
nally, the IPPHS study conﬁrmed that cirrhosis was a risk
factor for PAH.
188 Portal hypertension is not a rare cause
of PAH the proportion of patients with porto-pulmonary
hypertension was 8% in the NIH registry. Surgical porto-
systemic shunts increased the occurrence of PH in pa-
tients with portal hypertension since, in a retrospective
study, approximately 65% of the patients with PAH
underwent surgical shunts while 35% did not.
189 These
ﬁndings strongly suggest that the development of PAH
in patients with portal hypertension is related to the
development of portosystemic shunts rather than portal
hypertension per se. The presence of chronic parenchy-
mal liver disease and its severity is not associated with
the risk of PAH since this complication may occur in pa-
tients with extrahepatic portal hypertension.
189 Simi-
larly, the degree of portal hypertension estimated by
the hepatic venous pressure gradient and systemic hae-
modynamic changes are not associated with the develop-
ment of PAH.
184 Only the duration of portal hypertension
could increase the risk of developing PAH.
Pathogenesis – The mechanism whereby portal hyper-
tension facilitates the development of PAH remains un-
known.
185 The presence of porto-systemic shunt might
allow vasoconstrictive and vasoproliferative substances,
normally cleared by the liver, to reach the pulmonary
circulation. Serotonin produced by the enterochromafﬁn
cells of the intestine may be one of these substances.
Histopathological ﬁndings of porto-pulmonary hyperten-
sion are indistinguishable from those commonly observed
in IPAH.
190
Clinical picture and investigations – The clinical pic-
ture of patients with porto-pulmonary hypertension may
be indistinguishable from that of IPAH or may include a
combination of symptoms and signs of the underlying li-
ver disease.
185
Echocardiographic screening for the detection of PH in
patients with liver diseases is appropriate in symptomatic
patients and/or in candidates for liver transplantation. A
RHC should be performed in all cases with increased SPAP
in order to clarify the underlying haemodynamic changes
and deﬁne prognostic and therapeutic implications.
Haemodynamically, compared with patients with
IPAH, patients with porto-pulmonary hypertension have
a signiﬁcantly higher cardiac output and signiﬁcantly
lower systemic vascular resistance and PVR.
191 The diag-
nosis of portal hypertension with a Swan Ganz catheter
at the time of RHC requires the determination of a gradi-
ent between free and occluded (wedge) hepatic vein
pressure or hepatic venous pressure gradient, of more
than 10 mmHg (normal is <5 mmHg).
67
In a retrospective study,
185 patients with porto-pul-
monaryhypertensionhadabetterrateofsurvivalthanpa-
tients with IPAH, although there is some debate on this
issue.
192
Treatment – The treatment of porto-pulmonary
hypertension can be challenging and has not been thor-
oughly studied. Supplemental oxygen should be used as
needed to maintain arterial oxygen saturations >90%.
Diuretic therapy should be utilised to control volume
overload, oedema, and ascites. Anticoagulant therapy
has not been carefully studied in this population, and
should probably be avoided in patients with impaired he-
patic function and low platelet counts, and in patients at
increased risk of bleeding due to gastroesophageal vari-
ces. In the absence of a markedly increased cardiac out-
put, and relatively low PVR, patients with mild to
moderate PH should have acute vasoreactivity assessed
in the catheterisation laboratory. If such patients dem-
onstrate a favourable acute response to vasodilator, con-
sideration should be given to the cautious introduction of
a CCB. Betablockers which are normally used to treat
portal hypertension and reduce the risk of variceal bleed-
ing, may be poorly tolerated in cases of associated PAH
due to the negative inotropic effect on the right ventric-
ular myocardium.
There have been a number of case reports and small
case series describing the use of iv epoprostenol for
treatment of porto-pulmonary hypertension.
188,193,194 It
appears as though patients with porto-pulmonary hyper-
tension respond to chronic iv epoprostenol in a manner
somewhat similar to that of patients with IPAH. How-
ever, an increased incidence of ascites and splenomegaly
with this treatment has been reported.
195
Signiﬁcant PAH can substantially increase the risk
associated with liver transplantation and usually PAH is
a contraindication if mean PAP is P35 mmHg and/or
PVR is P250 dynes s cm.
196 It is occasionally possible to
reduce mPAP and PVR making a borderline candidate
for liver transplantation an acceptable one through
aggressive treatment of their PAH including the use of
epoprostenol.
192 In cases thought to have such severe
disease as to require multi-organ transplantation such
as combined liver and (heart-) lung transplantation the
risks are considered to be very high.
198
Some patients seem to demonstrate improvement in
their PAH following liver transplantation.
199 This may
be particularly true for those with a relatively high car-
diac output pre-transplantation, which then decreases
following successful transplantation. Other patients
may develop worsening of their PAH well after liver
transplantation. Occasionally, it may be possible to wean
a patient off iv epoprostenol following liver transplanta-
tion. This should probably be done very gradually, under
close observation.
Due to its potential for hepatoxicity, most experts
would probably recommend avoiding an oral endothelin
antagonist, e.g. bosentan in this population. Despite case
series from expert centres with favourable results, the
risk-to-beneﬁt ratio of endothelin receptor antagonists
in patients with liver disease need to be carefully evalu-
ated on a long-term basis.
Pulmonary arterial hypertension associated to
HIV infection
Incidence – PAH is a rare but well-documented complica-
tion of HIV infection; more than 200 cases have been re-
2270 ESC Guidelinesported in the literature.
19,200,201 Currently non-infectious
cardiovascular manifestations of HIV infection such as
dilated cardiomyopathy, pericardial effusion, non-bacte-
rial thrombotic endocarditis, accelerated atherosclerosis
and PAH are more commonly detected as a result of long-
er survival and better prophylaxis against opportunistic
infections.
202 In a large case control study, 3349 HIV-in-
fected patients over a period of 5.5 years demonstrated
a cumulative incidence of PH of 0.57%, resulting in an an-
nual incidence of 0.1%.
203
Pathogenesis – The mechanism of the development of
PAH is unknown. An indirect action of HIV through second
messengers such as cytokines,
204 growth factors,
204 or
ET-1
205 is strongly suspected because of the absence of
viral DNA in pulmonary endothelial cells.
204,206 This
hypothesis is reinforced by the presence of perivascular
inﬂammatory cells in HIV-associated PAH.
207,208 In addi-
tion, genetic predisposition can be also invoked because
this complication affects only a minority of HIV-infected
patients. The absence of germline BMPR2 mutation in a
subset of 30 tested patients with HIV-associated PAH
suggests that other susceptibility factors are
involved.
209
Clinical picture and investigations – HIV-related PAH
shows similar clinical, haemodynamic and histological
ﬁndings as IPAH and it does not appear to be related to
the route of HIV transmission nor to the degree of immu-
nosuppression.
210 HIV patients may often be also in-
fected by hepatitis B and C viruses and a concomitant
liver disease may be present.
Echocardiographic screening for the detection of PH
in patients with HIV infection is required in symptomatic
patients. A careful exclusion of other causes of PH such
as left heart and parenchymal lung and liver diseases
are necessary.
RHC is recommended in all cases of suspected PAH
associated with HIV infection to conﬁrm the diagnosis,
determine severity, and rule out left sided heart disease.
Mortality of patients with HIV-associated PAH is
mainly related to PAH itself, rather than to other compli-
cations of HIV infection;
210 PAH is an independent pre-
dictor of mortality in these patients.
203
Treatment – In HIV-associated PAH, therapeutic op-
tions are less well established as compared to other
forms of PAH. Oral anticoagulation is often contraindi-
cated because of frequent reduced platelet counts, difﬁ-
culty with compliance and potential drug interactions
between HIV medications and warfarin.
Acute vasoreactivity tests and long term beneﬁcial ef-
fect of CCB have not been reported in this PAH subgroup.
One uncontrolled open study of 6 patients with severe
HIV-associated PAH
128 suggests that continuous infusion
of epoprostenol might be effective in improving func-
tional status and haemodynamics up to 12–47 months.
Lung transplantation is considered not advisable in this
population.
The role of highly active antiretroviral therapy in the
management of HIV-associated PAH remains to be estab-
lished. A beneﬁcial effect on pulmonary haemodynamics
was observed in patients treated with nucleoside reverse
transcriptase inhibitors.
203 A single case report of long-
term haemodynamic improvement with this treatment,
without the associated use of any vasodilator agents,
has recently been published.
211 Lastly, in a large mono-
centric case series of 82 patients,
209 univariate analysis
indicated that CD4 count (>212 cells mm
3), combination
antiretroviral therapy, and the use of epoprostenol infu-
sion, were associated with an improved survival. On mul-
tivariate analysis, only CD4 lymphocyte count was an
independent predictor of survival, presumably because
combination antiretroviral therapy and epoprostenol
infusion were strongly linked in this study population.
Recently, clinical and haemodynamic favourable re-
sults have been shown with the use of bosentan in a ser-
ies of 16 HIV-related PAH patients.
212
In summary, uncontrolled studies suggest that pa-
tients with severe HIV-associated PAH may respond
favourably to combination antiretroviral therapy, epo-
prostenol and possibly to bosentan. However, epoprost-
enol as well as endothelin receptor antagonists and PDE
type 5 inhibitors should be evaluated in this patient pop-
ulation in controlled randomised trials.
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Pulmonary arterial hypertension associated to
connective tissue diseases
Incidence – PH is a well-known complication of CTD such
as systemic sclerosis,
214 systemic lupus erythemato-
sus,
215 mixed CTD,
216 and to a lesser extent, rheumatoid
arthritis, dermatopolymyositis, and primary Sjo ¨gren’s
syndrome.
217 In these patients, PAH may occur in associ-
ation with interstitial ﬁbrosis or as a result of direct pro-
liferative vascular involvement in the absence of
signiﬁcant parenchymal disease or chronic hypoxia. In
addition, pulmonary venous hypertension from left heart
disease can be present. It is imperative to determine
which mechanism is operative, as treatment may be
quite different for each process.
Estimation of the prevalence of PAH in patients with
CTD is difﬁcult because of the lack of consistent epidemi-
ological data. Estimated prevalence of PAH in these pa-
tients is highly variable, according to the deﬁnition of
PAH, the method used for assessing PA pressure and po-
tential bias concerning the study population.
4
Systemic sclerosis, particularly in its limited variant
previously deﬁned as CREST syndrome (calcinosis, Ray-
naud’s disease, oesophageal dysmotility, sclerodactyly,
and telangiectasia), represents the main CTD associated
with PAH. The recently completed registry study of PH in
722 patients with systemic sclerosis in the UK, showed
the prevalence at around 12%.
214 In another series of
930 patients with systemic sclerosis the cumulative inci-
dence of PH was 13%.
49 However, in a population-based
approach the prevalence of PH was 2.6% in 3778 pa-
tients.
218 In the NIH registry, among 236 cases of unex-
plained PAH, 18 were associated with CTD (8%).
48 In
several PAH centres, more than 10% of the patients dis-
playing severe PAH have an associated CTD, most often
the CREST variant of scleroderma.
Pathogenesis – Histopathological changes in PAH
associated with CTD are generally indistinguishable from
ESC Guidelines 2271those of classical IPAH. Moreover, the whole spectrum of
pulmonary vascular pathology has been described in
these patients, including PVOD disease and PCH. The
pathophysiological mechanisms leading to PAH in pa-
tients with CTD diseases remain unknown. A pulmonary
vasospasm, the so-called pulmonary Raynaud’s phenom-
enon, hypothetically could play a role. The presence of
antinuclear antibodies, rheumatoid factor, immunoglob-
ulin-G, and complement fractions deposits in the wall of
pulmonary vessels suggest a role for an immunological
mechanism.
Clinical picture and investigations – Compared with
patients with IPAH, patients with PAH associated with
CTD are mainly women, are older, have a signiﬁcantly
lower cardiac output, and show a trend toward a shorter
survival. In the UK registry, the average time between
diagnosis of systemic sclerosis and PAH was 14 years,
and the condition was in general found in late middle
age (mean age 66 years).
Symptoms and clinical presentation are very similar to
IPAH and occasionally patients can be identiﬁed as hav-
ing an associated CTD by immunology screening tests.
HRCT scanning is useful mainly as an exclusionary test
for the presence or absence of signiﬁcant ﬁbrosis. The
mortality was conﬁrmed to be higher than that seen with
IPAH (40% one-year mortality for those with advanced
disease), and the predictors of outcome were the same
as for IPAH (RAP, PAP and cardiac index).
Echocardiographic screening for the detection of PH
has been suggested to be performed yearly in asymptom-
atic patients with the scleroderma spectrum of dis-
eases
49 and only in presence of symptoms in other CTD.
The rationale for screening asymptomatic patients is
not clear as we do not have evidence that treatments
are effective in this subset. In any case the early detec-
tion of any PAH-related symptom should prompt a com-
plete and careful echocardiographic assessment at any
time and in any patient with CTD.
As in other forms of PAH, right heart catheterisation is
recommended in all cases of suspected PAH associated
with CTD to conﬁrm the diagnosis, determine severity,
and rule out left sided heart disease.
Treatment – Treatment of patients with PAH associ-
ated with CTD appears more complex as compared to
IPAH. Immunosuppressive therapy seems to be effective
only in a minority of patients mainly suffering from con-
ditions other than scleroderma.
The rate of acute vasoreactivity and of a long-term
favourable response to CCB treatment is lower compared
to IPAH. Also the risk-to-beneﬁt ratio of oral anticoagu-
lation is not well understood.
Continuous epoprostenol therapy has been shown to
improve exercise capacity, symptoms and haemodynam-
ics in a 3 months randomised trial of patients suffering
from the scleroderma spectrum of the disease.
113 In this
study, no improvement in survival was documented.
Some retrospective analysis show that the effect of iv
epoprostenol on survival of IPAH patients seems to be
better as compared to scleroderma patients.
218,220
Continuous subcutaneous administration of treprosti-
nil was evaluated in a subset of 90 patients with PAH
and CTD, including systemic lupus erythematosus, diffuse
scleroderma, limited scleroderma and mixed CTD/over-
lap syndrome thatwere enrolledin thelargerRCT on PAH.
After 12 weeks, an improvement on exercise capacity,
symptoms of PAH, and haemodynamics was shown. Ad-
verse events included infusion site pain and typical side
effects related to prostaglandins.
221
A randomised double-blind study of 12 weeks, includ-
ing a subgroup of 47 patients with CTD, has shown that
bosentansigniﬁcantlyimprovedexercisecapacity ascom-
pared to placebo in this population. However, although a
similar treatment effect was achieved in patients with
IPAH and in those with PAH associated with scleroderma,
bosentan improved the walking distance from baseline in
IPAH patients (+46 m in the bosentan group versus  5mi n
the placebo group) whereas it prevented walk distance
deterioration of the scleroderma patients (+3 m in the
bosentan group versus  40 m in the placebo group).
144
In summary, in patients with PAH associated with CTD
responses to treatments and long-term survival seem to
be worse as compared to IPAH.
Pulmonary veno-occlusive disease and
pulmonary capillary haemangiomatosis
Incidence – Both PVOD and PCH are uncommon condi-
tions, but they are increasingly recognised as causes of
PAH.
222 Less than 200 cases of PVOD and PCH, combined,
have been reported in the literature.
Pathogenesis – As discussed in the clinical classiﬁca-
tion and pathology sections (see above), PVOD and PCH
are similar in some respects particularly in relation to
the changes in the pulmonary parenchyma, i.e. pulmon-
ary haemosiderosis, interstitial oedema and lymphatic
dilatation, and to pulmonary arterial intimal ﬁbrosis
and medial hypertrophy.
6
Of particular interest are reports of a familial occur-
rence in both PVOD and PCH,
223 as well as in PAH. Lastly,
BMPR2 mutation, the gene associated with familial PAH
and IPAH, has been documented in a patient with
PVOD.
224 These ﬁndings suggest that PVOD, PCH and
PAH may represent components of a spectrum of a single
disease.
Clinical picture and investigations – Clinical presen-
tation of these patients is often indistinguishable from
that of patients with IPAH. However, physical examina-
tion can demonstrate ﬁndings suggestive of a diagnosis
other than IPAH, such as digital clubbing and/or basilar
rales on chest auscultation. Case series indicate that
PVOD/PCH is associated with more severe hypoxaemia
and reduction of single-breath DLCO, while spirometry
and lung volume measurements are generally within nor-
mal limits. The signiﬁcant decrease in DLCO that is often
seen may be explained by chronic interstitial oedema
secondary to pulmonary venous obstruction. Haemody-
namic data are similar between PVOD/PCH and IPAH,
although in some patients, the hypoxaemia is out of pro-
portion to the degree of PAH and right heart dysfunction.
Interestingly, PWP is often normal despite the postcapil-
lary involvement. Indeed, the pathological changes usu-
2272 ESC Guidelinesally occur in the venules, often without involvement of
the larger veins. The static column of blood produced
during the measurement of PWP is unaffected by the
changes in the small pulmonary veins as long as a connec-
tion is maintained with the larger, unaffected pulmonary
veins which is where the pressure will be measured in the
occluded arterial segment.
Radiological data may be of great help in detecting
PVOD/PCH.
62,225–227 The presence of Kerley B lines,
pleural effusion and patchy irregularities on a standard
chest roentgenogram may provide important clues that
suggest the diagnosis. Thin-section CT of the chest has
characteristic changes. The most commonly reported
CT ﬁndings are a patchy centrilobular pattern of
ground-glass opacities, thickened septal lines, pleural
effusion, and mediastinal adenopathy. These abnormali-
ties strongly correlate with the development of
pulmonary oedema with iv infusion of epoprostenol:
ground glass opacities (GGO) were signiﬁcantly more fre-
quent in PVOD/PCH than in IPAH (p = 0.003). In PVOD/
PCH, GGO were abundant, with a random repartition.
Morphologic feature of GGO was important. A centrilob-
ular distribution (poorly deﬁned centrilobular nodular
opacities) was more frequent in PVOD/PCH (p = 0.03).
Conversely, a panlobular distribution (geographic regions
of lung attenuation with relatively well deﬁned borders)
was seen in the two groups and was not predictive. Sub-
pleural septal lines (p < 0.0001), and adenopathy
(p < 0.0001) were also signiﬁcantly more frequent in
PVOD/PCH than in IPAH. The association of these three
ﬁndings was very speciﬁc for PVOD in cases of PH (spec-
iﬁcity = 100%) with a 66% sensitivity. Therefore, on the
initial pre-treatment chest CT, association of GGO (par-
ticularly with a centrilobular distribution), septal lines,
and adenopathy are indicative of PVOD/PCH in patients
displaying PAH. Caution must be taken before initiating
vasodilator therapy in the presence of such radiological
abnormalities.
Additional investigational methods with which to
diagnose PVOD include bronchoscopy with broncho-alve-
olar lavage. Compared with IPAH, PVOD/PCH was charac-
terised by signiﬁcantly elevated broncho-alveolar lavage
cell counts. However, the percentage of macrophages,
lymphocytes and neutrophils was similar. As PVOD/PCH
affects the postcapillary vasculature, it is generally asso-
ciated with occult alveolar haemorrhage and haemosid-
erin-laden macrophages. In a recent series, the
percentage of haemosiderin-laden macrophages was
higher in PVOD than in IPAH (54 ± 37% versus 3 ± 6%,
p = 0.0006). The Golde score was markedly elevated in
PVOD (109 ± 97 versus 4 ± 10, p = 0.0004).
228 In conclu-
sion, combined evidence of PAH, elevated numbers of
haemosiderin-laden bronchoalveolar macrophages, and
interstitial lung inﬁltrates is very suggestive of a diagno-
sis of PVOD/PCH.
Treatment – In the new clinical classiﬁcation, PVOD
and PVH are included in the category termed PAH
associated with signiﬁcant venous or capillary involve-
ment. This subgroup probably requires similar manage-
ment as other PAH subgroups. However, the prognosis
seems worse, with a more rapid downhill course. In addi-
tion, vasodilators and especially epoprostenol have to be
used with great caution because of the high risk of pul-
monary oedema.
229,230 However, there are reports of
sustained clinical improvement in individual patients
treated with these medications. There are no data
regarding the use of newer medical therapies such as
endothelin receptor antagonists in the treatment of
PVOD/PCH. Use of any medical therapy in these patients
should be undertaken only at centres with extensive
experience in the diagnosis and management of PAH,
and patients must be apprised of the risks prior to treat-
ment. Atrial septostomy may be considered but is limited
by hypoxaemia, more common in PVOD/PCH than in
other classes of PAH. The only curative therapy for
PVOD/PCH is lung transplantation, and similar to IPAH
there are no eports of recurrence of disease following
transplantation.
Acknowledgements
The CPG wishes to thank the reviewers of a ﬁrst version
of these guidelines entitled ‘‘ESC Guidelines on Primary
Pulmonary Hypertension’’: Joern Carlsen, Denmark;
Sean Gaine, Ireland; Stefano Ghio, Italy; Marc Humbert,
France; Irene Lang, Austria; Patrizia Presbitero, Italy;
Pietro Zonzin, Italy.
Appendix A. Abbreviations
Pulmonary arterial hypertension related to risk factors or
associated conditions (APAH)
Bone morphogenetic protein receptor 2 (BMPR2)
Calcium channel blockers (CCB)
Cardiopulmonary exercise testing (CPET)
Computerised tomography (CT)
Chronic thromboembolic pulmonary hypertension (CTEPH)
Connective tissue disease (CTD)
Cyclic guanosine 3
0-5
0 monophosphate (cGMP)
Diffusion capacity for carbon monoxide (DLCO)
Endothelin-1 (ET-1),
European Agency for the Evaluation of Medicinal Products
(EMEA)
Familial pulmonary artery hypertension (FPAH)
Food and Drug Administration (FDA)
Ground glass opacities (GGO)
High resolution computerised tomography (HRCT)
Human immunodeﬁciency virus (HIV)
Idiopathic pulmonary arterial hypertension (IPAH)
Interstitial lung disease (ILD)
Intravenous (iv)
New York Heart Association (NYHA)
Nitric oxide (NO)
Persistent pulmonary hypertension of the newborn (PPHN)
Phophodiesterase (PDE)
Primary pulmonary hypertension (PPH)
Pulmonary arterial hypertension (PAH)
Pulmonary hypertension (PH)
Pulmonary arterial pressure (PAP)
(Continued on next page)
ESC Guidelines 2273References
1. Simonneau G, Galie N, Rubin L et al. Clinical classiﬁcation of
pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:S5–12.
2. D’Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with
primary pulmonary hypertension. Results from a national prospec-
tive registry. Ann Intern Med 1991;115:343–9.
3. Rubin LJ. Primary pulmonary hypertension. N Engl J Med
1997;336:111–7.
4. Galie N, Manes A, Uguccioni L et al. Primary pulmonary hyperten-
sion: insights into pathogenesis from epidemiology. Chest 1998;114
(3 Suppl):184S–94S.
5. Pietra GG, Edwards WD, Kay JM et al. Histopathology of primary
pulmonary hypertension. A qualitative and quantitative study of
pulmonary blood vessels from 58 patients in the National Heart,
Lung, and Blood Institute, Primary Pulmonary Hypertension Registry
[see comments]. Circulation 1989;80:1198–206.
6. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of
vasculopathies in pulmonary hypertension. 2004:S25–32.
7. Humbert M, Morrell N, Archer S et al. Cellular and molecular
pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol
2004;43:S13–24.
8. Lane KB, Machado RD, Pauciulo MW et al. Heterozygous germline
mutations in BMPR2, encoding a TGF-beta receptor, cause familial
primary pulmonary hypertension. The International PPH Consor-
tium. Nat Genet 2000;26:81–4.
9. Deng Z, Morse JH, Slager SL et al. Familial primary pulmonary
hypertension (gene PPH1) is caused by mutations in the bone
morphogenetic protein receptor-II gene. Am J Hum Genetr
2000;67:737–44.
10. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in
pulmonary hypertension. Circulation 2004;109:159–65.
11. Barst R, McGoon M, Torbicki A et al. Diagnosis and differential
assessment of pulmonary arterial hypertension. J Am Coll Cardiol
2004;43:S40–7.
12. Hoeper M, Oudiz R, Peacock A et al. End-points and clinical trial
designs in pulmonary arterial hypertension: clinical and regulatory
perspectives. J Am Coll Cardiol 2004;43:S48–55.
13. Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial
hypertension. Am J Respir Med 2003;2:123–37.
14. Galie N, Manes A, Branzi A. The endothelin system in pulmonary
arterial hypertension. Cardiovasc Res 2004;61:227–37.
15. Sastry BKS, Narasimhan C, Reddy NK et al. Clinical efﬁcacy of
sildenaﬁl in primary pulmonary hypertension*1: A randomized,
placebo-controlled, double-blind, crossover study. J Am College
Cardiol 2004;43:1149–53.
16. Committee for Practice Guidelines (CPG) of the European Society of
Cardiology. Recommendations for Task Force Creation and Report
Production A document for Task Force members and expert panels
responsible for the creation and production of Guidelines and
Expert Consensus Documents Committee for Practice Guidelines
(CPG) of the European Society of Cardiology; 2003. http://
www.escardio.org.
17. Hatano S, Strasser T. World Health Organization 1975 primary
pulmonary hypertension. Geneva: WHO; 1975.
18. Fishman AP. Primary pulmonary arterial hypertension: a look back.
J Am Coll Cardiol 2004;43:S2–4.
19. Humbert M, Nunes H, Sitbon O et al. Risk factors for pulmonary
arterial hypertension. Clin Chest Med 2001;22:459–75.
20. Hoeper MM, Niedermeyer J, Hoffmeyer F et al. Pulmonary hyper-
tension after splenectomy?. Ann Intern Med 1999;130:506–9.
21. Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell
disease: cardiac catheterization results and survival. Blood
2003;101:1257–61.
22. Atichartakarn V, Likittanasombat K, Chuncharunee S et al. Pul-
monary arterial hypertension in previously splenectomized patients
with beta-thalassemic disorders. Int J Hematol 2003;78:139–45.
23. Dingli D, Utz JP, Krowka MJ et al. Unexplained pulmonary hyperten-
sion in chronic myeloproliferative disorders. Chest 2001;120:801–8.
24. Humbert M, Labrune P, Simonneau G et al. Pulmonary arterial
hypertension and type I glycogen storage disease: the serotonin
hypothesis. Eur Respir J 2002;20:59–65.
25. Dawson A, Elias DJ, Rubenson D et al. Pulmonary hypertension
developing after alglucerase therapy in two patients with type 1
Gaucher disease complicated by the hepatopulmonary syndrome.
Ann Intern Med 1996;125:901–4.
26. TrembathRC,Thomson JR,MachadoRD et al.Clinicalandmolecular
genetic features of pulmonary hypertension in patients with hered-
itary hemorrhagic telangiectasia. N Engl J Med 2001;345:325–34.
27. Daliento L, Somerville J, Presbitero P et al. Eisenmenger syndrome.
Factors relating to deterioration and death. Eur Heart J
1998;19:1845–55.
28. Besterman E. Atrial septal defects with pulmonary hypertension. Br
Heart J 1961;23:587–98.
29. Hoffman JE, Rudolph AM. The natural history of ventricular septal
defects in infancy. Am J Cardiol 1985;16:634–53.
30. Steele P, Fuster V, Cohen M et al. Isolated atrial septal defect with
pulmonary vascular obstructive disease: long-term follow-up and
prediction of outcome after surgical correction. Circulation
1987;76:1037–42.
31. Vogel M, Berger F, Kramer A et al. Incidence of secondary
pulmonary hypertension in adults with atrial septal or sinus venosus
defects. Heart 1999;82:30–3.
32. Kidd L, Driscoll D, Gersony W et al. Second natural history study of
congenital heart defects. Results of treatment of patients with
ventricular septal defects. Circulation 1993;87:138–51.
33. Neumayer U, Stone S, Somerville J. Small ventricular septal defects
in adults. Eur Heart J 1988;19:1573–82.
34. Wood P. Primary pulmonary hypertension, with special reference to
the vasoconstrictive factor. Br Heart J 1958;20:557–65.
35. Yuan JX, Aldinger AM, Juhaszova M et al. Dysfunctional voltage-
gated K+ channels in pulmonary artery smooth muscle cells of
patients with primary pulmonary hypertension. Circulation
1998;98:1400–6.
36. Petkov V, Mosgoeller W, Ziesche R et al. Vasoactive intestinal
peptide as a new drug for treatment of primary pulmonary
hypertension. J Clin Invest 2003;111:1339–46.
37. Cowan KN, Heilbut A, Humpl T et al. Complete reversal of fatal
pulmonary hypertension in rats by a serine elastase inhibitor. Nat
Med 2000;6:698–702.
38. Du L, Sullivan CC, Chu D et al. Signaling molecules in nonfamilial
pulmonary hypertension. NE n g lJM e d2003;348:500–9.
39. Dorfmuller P, Perros F, Balabanian K et al. Inﬂammation in
pulmonary arterial hypertension. Eur Respir J 2003;22:358–63.
40. Eddahibi S, Humbert M, Fadel E et al. Serotonin transporter
overexpression is responsible for pulmonary artery smooth muscle
hyperplasia in primary pulmonary hypertension. J Clin Invest
2001;108:1141–50.
41. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin
normalizes plasma markers of endothelial cell injury and platelet
aggregation in primary pulmonary hypertension. Circulation
1997;96:2782–4.
42. Eisenberg PR, Lucore C, Kaufman L et al. Fibrinopeptide A
levels indicative of pulmonary vascular thrombosis in patients
Appendix A. Abbreviation (Continued)
Pulmonary artery systolic pressure (PASP)
Pulmonary capillary haemangiomatosis (PCH)
Pulmonary function tests (PFT)
Pulmonary vascular resistance (PVR)
Pulmonary veno-occlusive disease (PVOD)
Pulmonary wedge pressure (PWP)
Randomised controlled clinical trial (RCT)
Right atrial pressure (RAP)
Right heart catheterisation (RHC)
Right ventricular systolic pressure (RVSP)
Six-minute walk test (6MWT)
Transoesophageal echocardiography (TEE)
Transthoracic echocardiography (TTE)
Thromboxane A2 (TxA2)
Ventilation/perfusion (V/Q)
World Health Organisation (WHO)
2274 ESC Guidelineswith primary pulmonary hypertension. Circulation 1990;82:
841–847.
43. Christman BW, McPherson CD, Newman JH et al. An imbalance
between the excretion of thromboxane and prostacyclin metabo-
lites in pulmonary hypertension [see comments]. N Engl J Med
1992;327:70–5.
44. Thomson JR, Trembath RC. Primary pulmonary hypertension: the
pressure rises for a gene. J Clin Pathol 2000;53:899–903.
45. Tsukada T, Yokoyama K, Arai T et al. Evidence of association of the
ecNOS gene polymorphism with plasma NO metabolite levels in
humans. Biochem Biophys Res Commun 1998;245:190–3.
46. Pearson DL, Dawling S, Walsh WF et al. Neonatal pulmonary
hypertension – urea-cycle intermediates, nitric oxide production,
and carbamoyl-phosphate synthetase function. N Engl J Med
2001;344:1832–8.
47. Chaouat A, Coulet F, Favre C et al. Endoglin germline mutation in a
patient with hereditary hemorrhagic telangiectasia and dexfenﬂur-
amine-associated pulmonary arterial hypertension. Thorax
2004;59:446–8.
48. Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hyperten-
sion.Anationalprospectivestudy.AnnInternMed1987;107:216–23.
49. MacGregor AJ, Canavan R, Knight C et al. Pulmonary hypertension
in systemic sclerosis: risk factors for progression and consequences
for survival. Rheumatology (Oxford) 2001;40:453–9.
50. Ahearn GS, Tapson VF, Rebeiz A et al. Electrocardiography to
deﬁne clinical status in primary pulmonary hypertension and
pulmonary arterial hypertension secondary to collagen vascular
disease. Chest 2002;122:524–7.
51. Ommen SR, Nishimura RA, Hurrell DG et al. Assessment of right
atrial pressure with 2-dimensional and Doppler echocardiography: a
simultaneous catheterization and echocardiographic study. Mayo
Clin Proc 2000;75:24–9.
52. Borgeson DD, Seward JB, Miller Jr FA et al. Frequency of Doppler
measurable pulmonary artery pressures. J Am Soc Echocardiogr
1996;9:832–7.
53. Denton CP, Cailes JB, Phillips GD et al. Comparison of Doppler
echocardiography and right heart catheterization to assess pulmon-
ary hypertension in systemic sclerosis. Br J Rheumatol
1997;36:239–43.
54. Vachiery JL, Brimioulle S, Crasset V et al. False-positive diagnosis
of pulmonary hypertension by Doppler echocardiography. Eur Respir
J 1998;12:1476–8.
55. McQuillan BM, Picard MH, Leavitt M et al. Clinical correlates and
reference intervals for pulmonary artery systolic pressure among
echocardiographically normal subjects. Circulation
2001;104:2797–802.
56. Mukerjee D, St George D, Knight C et al. Echocardiography and
pulmonary function as screening tests for pulmonary arterial
hypertension in systemic sclerosis. Rheumatology 2004;43:461–6.
57. Hinderliter AL, Willis PW, Barst RJ et al. Effects of long-term
infusion of prostacyclin (epoprostenol) on echocardiographic mea-
sures of right ventricular structure and function in primary
pulmonary hypertension. Primary Pulmonary Hypertension Study
Group [see comments]. Circulation 1997;95:1479–86.
58. Galie N, Hinderliter AL, Torbicki A et al. Effects of the oral
endothelin-receptor antagonist bosentan on echocardiographic and
doppler measures in patients with pulmonary arterial hypertension.
J Am Coll Cardiol 2003;41:1380–6.
59. Pauwels RA, Buist AS, Calverley PM et al. Global strategy for the
diagnosis, management, and prevention of chronic obstructive
pulmonary disease. NHLBI/WHO Global Initiative for Chronic
Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir
Crit Care Med 2001;163:1256–76.
60. Kazerooni EA, Martinez FJ, Flint A et al. Thin-section CT obtained
at 10-mm increments versus limited three-level thin-section CT for
idiopathic pulmonary ﬁbrosis: correlation with pathologic scoring.
AJR Am J Roentgenol 1997;169:977–83.
61. Fedullo PF, Auger WR, Kerr KM et al. Chronic thromboembolic
pulmonary hypertension. New England J Med 2001;345:1465–72.
62. Resten A, Maitre S, Capron F et al. Pulmonary hypertension: CT
ﬁndings in pulmonary veno-occlusive disease. J Radiol
2003;84:1739–45.
63. Ley S, Kreitner KF, Fink C et al. Assessment of pulmonary
hypertension by CT and MR imaging. Eur Radiol 2004;14:359–68.
64. Dartevelle P, Fadel E, Mussot S et al. Chronic thromboembolic
pulmonary hypertension. Eur Respir J 2004;23:637–48.
65. Rich S, Kieras K, Groves B et al. Antinuclear antibodies in primary
pulmonary hypertension. J Am Coll Cardiol 1986;8:1307–11.
66. Albrecht T, Blomley MJ, Cosgrove DO et al. Non-invasive diagnosis
of hepatic cirrhosis by transit-time analysis of an ultrasound
contrast agent. Lancet 1999;353:1579–83.
67. Naeije R. Hepatopulmonary syndrome and portopulmonary hyper-
tension. Swiss Medical Weekly 2003;133:163–9.
68. Miyamoto S, Nagaya N, Satoh T et al. Clinical correlates and
prognostic signiﬁcance of six-minute walk test in patients with
primary pulmonary hypertension. Comparison with cardiopulmonary
exercise testing. Am J Respir Crit Care Med 2000;161:487–92.
69. Wensel R, Opitz CF, Anker SD et al. Assessment of survival in
patients with primary pulmonary hypertension: importance of
cardiopulmonary exercise testing. Circulation 2002;106:319–24.
70. Galie N, Manes A, Branzi A. The new clinical trials on pharmaco-
logical treatment in pulmonary arterial hypertension. Eur Respir J
2002;20:1037–49.
71. Peacock A, Naeije R, Galie N et al. End-points for clinical trials in
pulmonary arterial hypertension. Eur Respir J 2004;23:947–53.
72. Guyatt GH, Sullivan MJ, Thompson PJ et al. The 6-minute walk: a
new measure of exercise capacity in patients with chronic failure.
Can Med Assoc J 1985;132:919–23.
73. Paciocco G, Martinez F, Bossone E et al. Oxygen desaturation on
the six-minute walk test and mortality in untreated primary
pulmonary hypertension. Eur Respir J 2001;17:647–52.
74. Barst RJ, McGoon M, Mc Laughlin VV et al. Beraprost therapy for
pulmonary arterial hypertension. J Am Coll Cardiol
2003;41:2115–25.
75. Barst RJ, Langleben D, Frost A et al. Sitaxsentan therapy for
pulmonary arterial hypertension. Am J Respir Crit Care Med
2004;169:441–7.
76. Sandoval J, Gaspar J, Pulido T et al. Graded balloon dilation atrial
septostomy in severe primary pulmonary hypertension. A therapeu-
tic alternative for patients nonresponsive to vasodilator treatment.
J Am Coll Cardiol 1998;32:297–304.
77. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary
hypertension: the impact of epoprostenol therapy. Circulation
2002;106:1477–82.
78. McLaughlin V, Sitbon O, Rubin L et al. The effect of ﬁrst-line
Bosentan on survival of patients with primary pulmonary hyperten-
sion. Am J Respir Crit Care Med 2003;167:A442.
79. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-
channel blockers on survival in primary pulmonary hypertension
[see comments]. N Engl J Med 1992;327:76–81.
80. Sitbon O, Humbert M, Jagot JL et al. Inhaled nitric oxide as a
screening agent for safely identifying responders to oral calcium-
channel blockers in primary pulmonary hypertension. Eur Respir J
1998;12:265–70.
81. Sitbon O, Humbert M, Ioos V et al. Who beneﬁts from long-term
calcium-channel blocker therapy in primary pulmonary hyperten-
sion?. Am J Resp Crit Care Med 2003;167.
82. Weir EK, Rubin LJ, Ayres SM et al. The acute administration of
vasodilators in primary pulmonary hypertension. Experience from
the National Institutes of Health Registry on Primary Pulmonary
Hypertension. Am Rev Respir Dis 1989;140:1623–30.
83. Galie N, Ussia G, Passarelli P et al. Role of pharmacologic tests in
the treatment of primary pulmonary hypertension. Am J Cardiol
1995;75:55A–62A.
84. McLaughlin VV, Genthner DE, Panella MM et al. Reduction in
pulmonary vascular resistance with long-term epoprostenol (pros-
tacyclin) therapy in primary pulmonary hypertension [see com-
ments]. NE n g lJM e d1998;338:273–7.
85. Galie N, Seeger W, Naeije R et al. Comparative analysis of clinical
trials and evidence-based treatment algorithm in pulmonary arte-
rial hypertension. J Am Coll Cardiol 2004;43:S81–8.
86. Nootens M, Kaufman E, Rich S. Short-term effectiveness of
nifedipine in secondary pulmonary hypertension. 1993:1476.
87. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous
epoprostenol infusion in primary pulmonary hypertension: prognos-
tic factors and survival. J Am Coll Cardiol 2002;40:780–8.
88. Eysmann SB, Palevsky HI, Reichek N et al. Two-dimensional and
Doppler-echocardiographic and cardiac catheterization correlates
ESC Guidelines 2275of survival in primary pulmonary hypertension. Circulation
1989;80:353–60.
89. Raymond RJ, Hinderliter AL, Willis PW et al. Echocardiographic
predictors of adverse outcomes in primary pulmonary hypertension.
J Am Coll Cardiol 2002;39:1214–9.
90. Tei C, Dujardin KS, Hodge DO et al. Doppler echocardiographic
index for assessment of global right ventricular function [see
comments]. J Am Soc Echocardiogr 1996;9:838–47.
91. Yeo TC, Dujardin KS, Tei C et al. Value of a Doppler-derived index
combining systolic and diastolic time intervals in predicting
outcome in primary pulmonary hypertension. Am J Cardiol
1998;81:1157–61.
92. Raffy O, Azarian R, Brenot F et al. Clinical signiﬁcance of the
pulmonary vasodilator response during short-term infusion of
prostacyclin in primary pulmonary hypertension. Circulation
1996;93:484–8.
93. Voelkel MA, Wynne KM, Badesch DB et al. Hyperuricemia in severe
pulmonary hypertension. Chest 2000;117:19–24.
94. Nagaya N, Nishikimi T, Uematsu M et al. Plasma brain natriuretic
peptide as a prognostic indicator in patients with primary
pulmonary hypertension. Circulation 2000;102:865–70.
95. Nootens M, Kaufmann E, Rector T et al. Neurohormonal activation
in patients with right ventricular failure from pulmonary hyperten-
sion: relation to hemodynamic variables and endothelin levels. JA m
Coll Cardiol 1995;26:1581–5.
96. Rubens C, Ewert R, Halank M et al. Big endothelin-1 and endothelin-
1 plasma levels are correlated with the severity of primary
pulmonary hypertension. Chest 2001;120:1562–9.
97. Torbicki A, Kurzyna M, Kuca P et al. Detectable serum cardiac
troponin T as a marker of poor prognosis among patients with
chronic precapillary pulmonary hypertension. Circulation
2003;108:844–8.
98. Galie N. Do we need controlled clinical trials in pulmonary arterial
hypertension? Eur Respir J 2001;17:1–3.
99. Badesch BD, Abman SH, Ahearn GS et al. Medical therapy for
pulmonary arterial hypertension. ACCP Evidence-Based Guidelines
for Clinical Practice. Chest 2004;126:355–625.
100. Manes A, Galie ` N, Branzi A. Women and pulmonary arterial
hypertension. Eur Respir J(Monograph) 2003;8:219–27.
101. Nelson DM, Main E, Crafford W et al. Peripartum heart failure due
to primary pulmonary hypertension. Obstet Gynecol
1983;62:58s–63s.
102. Weiss BM, Zemp L, Seifert B et al. Outcome of pulmonary vascular
disease in pregnancy: a systematic overview from 1978 through
1996. J Am Coll Cardiol 1998;31:1650–7.
103. Nootens M, Rich S. Successful management of labor and delivery in
primary pulmonary hypertension. Am J Cardiol 1993;71:1124–5.
104. Expert consensus document on management of cardiovascular
diseases during pregnancy. Eur Heart J 2003;24:761–81.
105. Abenhaim L, Moride Y, Brenot F et al. Appetite-suppressant drugs
and the risk of primary pulmonary hypertension. International
Primary Pulmonary Hypertension Study Group [see comments]. N
Engl J Med 1996;335:609–16.
106. Deanﬁeld J, Thaulow E, Warnes C et al. Management of grown up
congenital heart disease. Eur Heart J 2003;24:1035–84.
107. Sanguinetti M, Galie N, Magelli C et al. Precapillary pulmonary
hypertension: effect of Captopril. G Ital Cardiol 1982;12:436–41.
108. Girgis A, Sanson-Fisher RW. Breaking bad news: consensus guide-
lines for medical practitioners. J Clin Oncol 1995;13:2449–56.
109. Stewart M, Davidson K, Meade D et al. Group support for couples
coping with a cardiac condition. J Adv Nurs 2001;33:190–9.
110. Moser KM, Fedullo PF, Finkbeiner WE et al. Do patients with
primary pulmonary hypertension develop extensive central
thrombi?. Circulation 1995;91:741–5.
111. Fuster V, Steele PM, Edwards WD et al. Primary pulmonary
hypertension: natural history and the importance of thrombosis.
Circulation 1984;70:580–7.
112. Frank H, Mlczoch J, Huber K et al. The effect of anticoagulant
therapy in primary and anorectic drug-induced pulmonary hyper-
tension. Chest 1997;112:714–21.
113. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous
epoprostenol for pulmonary hypertension due to the scleroderma
spectrum of disease. A randomized, controlled trial [see com-
ments]. Ann Intern Med 2000;132:425–34.
114. Sandoval J, Aguirre JS, Pulido T et al. Nocturnal oxygen therapy in
patients with the eisenmenger syndrome. Am J Respir Crit Care
Med 2001;164:1682–7.
115. Rich S, Seidlitz M, Dodin E et al. The short-term effects of digoxin
in patients with right ventricular dysfunction from pulmonary
hypertension. Chest 1998;114:787–92.
116. Naeije R, Vachiery F. Medical treatment of pulmonary hyperten-
sion. Clin Chest Med 2004;22:517–27.
117. Rich S, Brundage BH. High-dose calcium channel-blocking therapy
for primary pulmonary hypertension: evidence for long-term
reduction in pulmonary arterial pressure and regression of right
ventricular hypertrophy. Circulation 1987;76:135–41.
118. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary
pulmonary hypertension in children. Circulation
1999;99:1197–208.
119. Rich S, Kaufmann E. High dose titration of calcium channel blocking
agents for primary pulmonary hypertension: guidelines for short-
term drug testing. J Am Coll Cardiol 1991;18:1323–7.
120. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane
and prostacyclin receptors elicits opposing effects on vascular
smooth muscle cell growth and mitogen-activated protein kinase
signaling cascades. Mol Pharmacol 1995;48:890–6.
121. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous
intravenous epoprostenol (prostacyclin) with conventional therapy
for primary pulmonary hypertension. The Primary Pulmonary
Hypertension Study Group [see comments]. N Engl J Med
1996;334:296–302.
122. Rubin LJ, Mendoza J, Hood M et al. Treatment of primary
pulmonary hypertension with continuous intravenous prostacyclin
(epoprostenol). Results of a randomized trial. Ann Intern Med
1990;112:485–91.
123. Robbins IM, Gaine SP, Schilz R et al. Epoprostenol for treatment of
pulmonary hypertension in patients with systemic lupus erythemat-
osus [see comments]. Chest 2000;117:14–8.
124. McLaughlin VV, Genthner DE, Panella MM et al. Compassionate use
of continuous prostacyclin in the management of secondary
pulmonary hypertension: a case series [see comments]. Ann Intern
Med 1999;130:740–3.
125. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for
pulmonary hypertension with associated congenital heart defects.
Circulation 1999;99:1858–65.
126. Kuo PC, Johnson LB, Plotkin JS et al. Continuous intravenous
infusion of epoprostenol for the treatment of portopulmonary
hypertension. Transplantation 1997;63:604–6.
127. Bakst AE, Gaine SP, Rubin LJ. Continuous intravenous epoprostenol
therapy for pulmonary hypertension in Gaucher’s disease. Chest
1999;116:1127–9.
128. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-
associated pulmonary hypertension. Am J Respir Crit Care Med
2000;162:1846–50.
129. Higenbottam T, Butt AY, McMahon A et al. Long-term intravenous
prostaglandin (epoprostenol or iloprost) for treatment of severe
pulmonary hypertension. Heart 1998;80:151–5.
130. Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous
infusion of treprostinil, a prostacyclin analogue, in patients with
pulmonary arterial hypertension. A double-blind, randomized,
placebo-controlled trial. Am J Respir Crit Care Med
2002;165:800–4.
131. McLaughlin VV, Gaine SP, Barst RJ et al. Efﬁcacy and safety of
treprostinil: an epoprostenol analog for primary pulmonary hyper-
tension. J Cardiovasc Pharmacol 2003;41:293–9.
132. Vachiery JL, Hill N, Zwicke D et al. Transitioning from i.v.
epoprostenol to subcutaneous treprostinil in pulmonary arterial
hypertension. Chest 2002;121:1561–5.
133. Galie N, Humbert M, Vachiery JL et al. Effects of beraprost sodium,
an oral prostacyclin analogue, in patients with pulmonary arterial
hypertension: a randomised, double-blind placebo-controlled trial.
J Am Coll Cardiol 2002;39:1496–502.
134. Hoeper MM, Olschewski H, Ghofrani HA et al. A comparison of the
acute hemodynamic effects of inhaled nitric oxide and aerosolized
iloprost in primary pulmonary hypertension. German PPH study
group. J Am Coll Cardiol 2000;35:176–82.
135. Olschewski H, Simonneau G, Galie N et al. Inhaled Iloprost in severe
pulmonary hypertension. N Engl J Med 2002;347:322–9.
2276 ESC Guidelines136. Hoeper MM, Schwarze M, Ehlerding S et al. Long-term treatment of
primary pulmonary hypertension with aerosolized iloprost, a pros-
tacyclin analogue. N Engl J Med 2000;342:1866–70.
137. Olschewski H, Ghofrani HA, Walmrath D et al. Inhaled prostacyclin
and iloprost in severe pulmonary hypertension secondary to lung
ﬁbrosis. Am J Respir Crit Care Med 1999;160:600–7.
138. Higenbottam TW, Butt AY, Dinh-Xaun AT et al. Treatment of
pulmonary hypertension with the continuous infusion of a prosta-
cyclin analogue, iloprost. Heart 1998;79:175–9.
139. Ewert R, Opitz C, Wensel R et al. Iloprost as inhalational and
intravenous long-term treatment of patients with primary pulmon-
ary hypertension. Register of the Berlin Study Group for Pulmonary
Hypertension. Z Kardiol 2000;89:987–99.
140. Stewart DJ, Levy RD, Cernacek P et al. Increased plasma endothe-
lin-1 in pulmonary hypertension: marker or mediator of disease?.
Ann Intern Med 1991;114:464–9.
141. Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-
1 in the lungs of patients with pulmonary hypertension. N Engl J
Med 1993;328:1732–9.
142. Clozel M, Breu V, Gray GA et al. In vivo pharmacology of Ro 46-
2005, the ﬁrst synthetic nonpeptide endothelin receptor antagonist:
implications for endothelin physiology. J Cardiovasc Pharmacol
1993;22:S377–9:S377-S379.
143. Channick R, Badesch DB, Tapson VF et al. Effects of the dual
endothelin receptor antagonist bosentan in patients with pulmonary
hypertension: a placebo-controlled study. J Heart Lung Transplant
2001;20:262–3.
144. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for
pulmonary arterial hypertension. N Engl J Med 2002;346:896–903.
145. Fattinger K, Funk C, Pantze M et al. The endothelin antagonist
bosentan inhibits the canalicular bile salt export pump: A potential
mechanism for hepatic adverse reactions. Clin Pharmacol Thera-
peutics 2001;69:223–31.
146. Sitbon O, Badesch DB, Channick RN et al. Effects of the dual
endothelin receptor antagonist bosentan in patients with pulmonary
arterial hypertension: a 1-year follow-up study. Chest
2003;124:247–54.
147. Kim NS, Channick R, Rubin LJ. Successful withdrawal of chronic
epoprostenol therapy for pulmonary arterial hypertension. Chest
2003;124:1612–5.
148. Barst RJ, Ivy D, Dingemanse J et al. Pharmacokinetics, safety, and
efﬁcacy of bosentan in pediatric patients with pulmonary arterial
hypertension. Clin Pharmacol Ther 2003;73:372–82.
149. Barst RJ, Rich S, Widlitz A et al. Clinical efﬁcacy of sitaxsen-
tan, an endothelin-A receptor antagonist, in patients with
pulmonary arterial hypertension: open-label pilot study. Chest
2002;121:1860–8.
150. Rubin LJ, Galie N, Badesch BD, et al. Ambrisentan improves
exercise capacity and clinical measures in pulmonary arterial
hypertension (PAH). Am J Crit Care Med 2004:169.A210.
151. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of
sildenaﬁl. J Biol Chem 1999;274:13729–32.
152. Manes A, Tantini B, Galie N et al. Effects of sildenaﬁl on growth and
viability of cultured human pulmonary artery smooth muscle cells. J
Am Coll Cardiol 2003;41:223A.
153. Polson JB, Strada SJ. Cyclic nucleotide phosphodiesterases and
vascular smooth muscle. Annu Rev Pharmacol Toxicol 1996;36:
403–427.
154. Cohen AH, Hanson K, Morris K et al. Inhibition of cyclic 30-50-
guanosine monophosphate-speciﬁc phosphodiesterase selectively
vasodilates the pulmonary circulation in chronically hypoxic rats. J
Clin Invest 1996;97:172–9.
155. Hanson KA, Burns F, Rybalkin SD et al. Developmental changes in
lung cGMP phosphodiesterase-5 activity, protein, and message. Am
J Respir Crit Care Med 1998;158:279–88.
156. Hanson KA, Ziegler JW, Rybalkin SD et al. Chronic pulmonary
hypertension increases fetal lung cGMP phosphodiesterase activity.
Am J Physiol 1998;275:L931–41.
157. Prasad S, Wilkinson J, Gatzoulis MA. Sildenaﬁl in primary pulmonary
hypertension. N Engl J Med 2000;343:1342.
158. Bhatia S, Frantz RP, Severson CJ et al. Immediate and long-term
hemodynamic and clinical effects of sildenaﬁl in patients with
pulmonary arterial hypertension receiving vasodilator therapy.
Mayo Clin Proc 2003;78:1207–13.
159. Michelakis ED, Tymchak W, Noga M et al. Long-term treatment with
oral sildenaﬁl is safe and improves functional capacity and hemo-
dynamics in patients with pulmonary arterial hypertension. Circu-
lation 2003;108:2066–9.
160. Ghofrani HA, Schermuly RT, Rose F et al. Sildenaﬁl for long-term
treatment of nonoperable chronic thromboembolic pulmonary
hypertension. Am J Respir Crit Care Med 2003;167:1139–41.
161. Ghofrani HA, Wiedemann R, Rose F et al. Sildenaﬁl for treatment of
lung ﬁbrosis and pulmonary hypertension: a randomised controlled
trial. Lancet 2002;360:895–900.
162. Ghofrani A, for the Sildenaﬁl 1140 Study Group. Efﬁcacy and safety
of sildenaﬁl citrate in pulmonary arterial hypertension: results of a
multinational, randomized, double-blind, placebo-controlled trial;
American College of Chest Physicians, 2004.
163. Humbert M, Barst R, Robbins I et al. Combination of Epoprosterol
and Bosentan in pulmonary arterial hypertension: BREATHE-2. Eur
Respir J 2004;24:353–9.
164. Hoeper M, Taha N, Bekjarova A et al. Bosentan treatment in
patients with primary pulmonary hypertension receiving non-
parenteral prostanoids. Eur Respir J 2003;330–4.
165. Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenaﬁl as long-
term adjunct therapy to inhaled iloprost in severe pulmonary
arterial hypertension. J Am Coll Cardiol 2003;42:158–64.
166. Austen WG, Morrow AG, Berry WB. Experimental studies of the
surgical treatment of primary pulmonary hypertension. J Thorac
Cardiovasc Surg 1964;48:448–55.
167. Rozkovec A, Montanes P, Oakley CM. Factors that inﬂuence the
outcome of primary pulmonary hypertension. Br Heart J
1986;55:449–58.
168. Sandoval J, Rothman A, Pulido T. Atrial septostomy for pulmonary
hypertension. Clin Chest Med 2001;22:547–60.
169. Klepetko W, Mayer E, Sandoval J et al. Interventional and surgical
modalities of treatment for pulmonary arterial hypertension. JA m
Coll Cardiol 2004;43:S73–80.
170. Hertz MI, Taylor DO, Trulock EP et al. The registry of the
International Society for Heart and Lung Transplantation: Nine-
teenth Ofﬁcial Report 2002. J Heart Lung Transplant
2002;21:950–70.
171. Long W. Persistent pulmonary hypertension of the newborn
syndrome. In: Long WA, editor. Fetal and neonatal cardiol-
ogy. Philadelphia: WB Saunders; 1989. p. 627–55.
172. Weigel TJ, Hageman JR. National survey of diagnosis and manage-
ment of persistent pulmonary hypertension of the newborn. J
Perinatol 1990;10:369–75.
173. Clark RH, Kueser TJ, Walker MW et al. Low-dose nitric oxide
therapy for persistent pulmonary hypertension of the newborn.
Clinical Inhaled Nitric Oxide Research Group. N Engl J Med
2000;342:469–74.
174. Walsh MC, Stork EK. Persistent pulmonary hypertension of the
newborn. Rational therapy based on pathophysiology. Clin Perinatol
2001;28:609–27.. vii.
175. Sandoval J, Bauerle O, Gomez A et al. Primary pulmonary hyper-
tension in children: clinical characterization and survival. J Am Coll
Cardiol 1995;25:466–74.
176. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet
1998;352:719–25.. [published erratum appears in Lancet 1999
Jan 2;353(9146):74].
177. Barst R, Ivy D, Widlitz AC et al. Pharmacokinetics, safety, and
efﬁcacy of bosentan in pediatric patients with pulmonary arterial
hypertension. Clin Pharmacol Ther 2003;73:372–82.
178. Abrams D, Schulze-Neick I, Magee AG. Sildenaﬁl as a selective
pulmonary vasodilator in childhood primary pulmonary hyperten-
sion. Heart 2000;84:E4.
179. Vongpatanasin W, Brickner ME, Hillis LD et al. The Eisenmenger
syndrome in adults. Ann Intern Med 1998;128:745–55.
180. Hopkins WE, Ochoa LL, Richardson GW et al. Comparison of the
hemodynamics and survival of adults with severe primary pulmon-
ary hypertension or Eisenmenger syndrome. J Heart Lung Trans-
plant 1996;15:100–5.
181. Berman EB, Barst RJ. Eisenmenger’s syndrome: current manage-
ment. Prog Cardiovasc Dis 2002;45:129–38.
182. Sandoval J, Aguirre JS, Pulido T et al. Nocturnal oxygen therapy in
patients with the Eisenmenger syndrome. Am J Respir Crit Care Med
2001;164:1682–7.
ESC Guidelines 2277183. Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults.
Second of two parts. N Engl J Med 2000;342:334–42.. [published
erratum appears in N Engl J Med 2000 Mar 30;342(13):988].
184. Hadengue A, Benhayoun MK, Lebrec D et al. Pulmonary hyperten-
sion complicating portal hypertension: prevalence and relation to
splanchnic hemodynamics. Gastroenterology 1991;100: 520–528.
185. Herve P, Lebrec D, Brenot F et al. Pulmonary vascular disorders in
portal hypertension. Eur Respir J 1998;11:1153–66.
186. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hyperten-
sion and hepatopulmonary syndrome. Lancet 2004;363:1461–8.
187. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hyper-
tension and cirrhosis: are they related. Am Rev Respir Dis
1983;127:437–41.
188. The International Primary Pulmonary Hypertension Study (IPPHS).
Chest 1994;105:37S–41S.
189. Lebrec D, Capron JP, Dhumeaux D et al. Pulmonary hypertension
complicating portal hypertension. Am Rev Respir Dis
1979;120:849–56.
190. Ruttner JR, Bartschi JP, Niedermann R et al. Plexogenic pulmonary
arteriopathy and liver cirrhosis. Thorax 1980;35:133–6.
191. Kuo PC, Plotkin JS, Johnson LB et al. Distinctive clinical features of
portopulmonary hypertension [see comments]. Chest
1997;112:980–6.
192. Robalino BD, Moodie DS. Association between primary pulmonary
hypertension and portal hypertension: analysis of its pathophysiol-
ogy and clinical, laboratory and hemodynamic manifestations. JA m
Coll Cardiol 1991;17:492–8.
193. Plotkin JS, Kuo PC, Rubin LJ et al. Successful use of chronic
epoprostenol as a bridge to liver transplantation in severe porto-
pulmonary hypertension. Transplantation 1998;65:457–9.
194. Krowka MJ, Frantz RP, McGoon MD et al. Improvement in
pulmonary hemodynamics during intravenous epoprostenol
(prostacyclin): A study of 15 patients with moderate to
severe portopulmonary hypertension. Hepatology 1999;30: 641–8.
195. Findlay JY, Plevak DJ, Krowka MJ et al. Progressive splenomegaly
after epoprostenol therapy in portopulmonary hypertension. Liver
Transpl Surg 1999;5:362–5.
196. Krowka MJ, Plevak DJ, Findlay JY et al. Pulmonary hemodynamics
and perioperative cardiopulmonary-related mortality in patients
with portopulmonary hypertension undergoing liver transplanta-
tion. Liver Transpl 2000;6:443–50.
197. Tan HP, Markowitz JS, Montgomery RA et al. Liver transplantation
in patients with severe portopulmonary hypertension treated with
preoperative chronic intravenous epoprostenol. Liver Transpl
2001;7:745–9.
198. Pirenne J, Verleden G, Nevens F et al. Combined liver and (heart)
lung transplantation in liver transplant candidates with refractory
portopulmonary hypertension. Transplantation 2002;73:140–2.
199. Schott R, Chaouat A, Launoy A et al. Improvement of pulmonary
hypertension after liver transplantation. Chest 1999;115:1748–9.
200. Mitchell DM, Miller RF. AIDS and the lung: update 1995. 2. New
developments in the pulmonary diseases affecting HIV infected
individuals. Thorax 1995;50:294–302.
201. Mehta NJ, Khan IA, Mehta RN et al. HIV-related pulmonary hyper-
tension: analytic review of 131 cases. Chest 2000;118:1133–41.
202. Mehta NJ, Khan IA, Mehta RN et al. Acute coronary syndrome in
patients with human immunodeﬁciency virus disease. Angiology
2002;53:545–9.
203. Opravil M, Peche `re M, Speich R et al. HIV-associated primary
pulmonary hypertension. A case control study. Swiss HIV Cohort
Study. Am J Respir Crit Care Med 1997;155:990–5.
204. Humbert M, Monti G, Fartoukh M et al. Platelet-derived growth
factor expression in primary pulmonary hypertension: comparison
of HIV seropositive and HIV seronegative patients. Eur Respir J
1998;11:554–9.
205. Ehrenreich H, Rieckmann P, Sinowatz F et al. Potent stimulation of
monocytic endothelin-1 production by HIV-1 glycoprotein 120. J
Immunol 1993;150:4601–9.
206. Mette SA, Palevsky HI, Pietra GG et al. Primary pulmonary
hypertension in association with human immunodeﬁciency virus
infection. A possible viral etiology for some forms of hypertensive
pulmonary arteriopathy. Am Rev Respir Dis 1992;145:1196–200.
207. Tuder RM, Groves B, Badesch DB et al. Exuberant endothelial
cell growth and elements of inﬂammation are present in
plexiform lesions of pulmonary hypertension. Am J Pathol
1994;144:275–85.
208. Voelkel NF, Cool C, Lee SD et al. Primary pulmonary hypertension
between inﬂammation and cancer. Chest 1998;114:225S–30S.
209. Nunes H, Humbert M, Sitbon O et al. Prognostic factors for survival
in human immunodeﬁciency virus-associated pulmonary arterial
hypertension. Am J Respir Crit Care Med 2003;167:1433–9.
210. Petitpretz P, Brenot F, Azarian R et al. Pulmonary hypertension in
patients with human immunodeﬁciency virus infection. Comparison
with primary pulmonary hypertension. Circulation 1994;89:2722–7.
211. Speich R, Jenni R, Opravil M et al. Regression of HIV-associated
pulmonary arterial hypertension and long-term survival during
antiretroviral therapy. Swiss Med Wkly 2001;131:663–5.
212. Sitbon O, Gressin V, Speich R et al. Bosentan in pulmonary arterial
hypertension associated with HIV infection. Eur Respir J
2003;22:563s.
213. Hoeper M, Galie N, Simonneau G et al. New treatments for
pulmonary arterial hypertension. Am J Respir Crit Care Med
2002;165:1209–16.
214. Mukerjee D, St George D, Coleiro B et al. Prevalence and outcome
in systemic sclerosis associated pulmonary arterial hypertension:
application of a registry approach. Ann Rheum Dis
2003;62:1088–93.
215. Pan TL, Thumboo J, Boey ML. Primary and secondary pulmonary
hypertension in systemic lupus erythematosus. Lupus
2000;9:338–42.
216. Sanchez O, Humbert M, Sitbon O et al. Treatment of pulmonary
hypertension secondary to connective tissue diseases. Thorax
1999;54:273–7.
217. Fagan KA, Badesch DB. Pulmonary hypertension associated with
connective tissue disease. Prog Cardiovasc Dis 2002;45:
225–34.
218. Yoshida S, Katayama M. [Pulmonary hypertension in patients with
connective tissue diseases. Nippon Rinsho 2001;59:1164–7.
219. Humbert M, Sanchez O, Fartoukh M et al. Short-term and long-term
epoprostenol (prostacyclin) therapy in pulmonary hypertension
secondary to connective tissue diseases: results of a pilot study.
Eur Respir J 1999;13:1351–6.
220. Kuhn KP, Byrne DW, Arbogast PG et al. Outcome in 91 consecutive
patients with pulmonary arterial hypertension receiving epoprost-
enol. Am J Respir Crit Care Med 2003;167:580–6.
221. Oudiz R, Schilz R, Barst R et al. Treprostinil, a prostacyclin
analogue, in pulmonary arterial hypertension associated with
connective tissue disease. Chest 2004;126:420–7.
222. Holcomb Jr BW, Loyd JE, Ely EW et al. Pulmonary veno-occlusive
disease: a case series and new observations. Chest
2000;118:1671–9.
223. Langleben D, Heneghan JM, Batten AP et al. Familial pulmonary
capillary hemangiomatosis resulting in primary pulmonary hyper-
tension. Ann Intern Med 1988;109:106–9.
224. Runo JR, Vnencak-Jones CL, Prince M et al. Pulmonary veno-
occlusive disease caused by an inherited mutation in bone morpho-
genetic protein receptor II. Am J Respir Crit Care Med
2003;167:889–94.
225. Dufour B, Maitre S, Humbert M et al. High-resolution CT of the
chest in four patients with pulmonary capillary hemangiomatosis or
pulmonary venoocclusive disease. AJR Am J Roentgenol
1998;171:1321–4.
226. Resten A, Maitre S, Humbert M et al. Pulmonary hypertension: CT
of the chest in pulmonary venoocclusive disease. Am J Roentgenol
2004;183:65–70.
227. Swensen SJ, Tashjian JH, Myers JL et al. Pulmonary venoocclusive
disease: CT ﬁndings in eight patients. AJR Am J Roentgenol
1996;167:937–40.
228. Rabiller A, Humbert M, Sitbon M et al. Bronchoalveolar lavage as a
diagnostic tool in pulmonary hypertension: occult alveolar hemor-
rhage is a common feature of pulmonary venoocclusive disease. Am
J Resp Crit Care Med 2004;167:A276.
229. Palmer SM, Robinson LJ, Wang A et al. Massive pulmonary edema
and death after prostacyclin infusion in a patient with pulmonary
veno-occlusive disease. Chest 1998;113:237–40.
230. Humbert M, Maı ˆtre S, Capron F et al. Pulmonary edema compli-
cating continuous intravenous prostacyclin in pulmonary capillary
hemangiomatosis. Am J Respir Crit Care Med 1998;157:1681–5.
2278 ESC Guidelines